imidazole fungicide - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	imidazole fungicide	go back to main search page
Accession:	CHEBI:87068	browse the term
Definition:	Any imidazole antifungal agent that has been used as a fungicide.
Synonyms:	related_synonym:	imidazole fungicides

show annotations for term's descendants Sort by:
Rat (658) Mouse (666) Human (662) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (658)

cyazofamid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases transport
multiple interactions

ABCB1 protein results in increased transport of cyazofamid
cyazofamid affects the reaction [ABCB1 protein results in increased uptake of Digoxin]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of cyazofamid]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 2

increases uptake

ABCC2 protein results in increased uptake of cyazofamid

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily G member 2

increases uptake

ABCG2 protein results in increased uptake of cyazofamid

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

cytochrome P450, family 3, subfamily a, polypeptide 9

decreases expression

cyazofamid results in decreased expression of CYP3A5 mRNA

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

iodothyronine deiodinase 1

decreases activity

cyazofamid results in decreased activity of DIO1 protein

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

estrogen related receptor, alpha

increases activity

cyazofamid results in increased activity of ESRRA protein

NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268

G

solute carrier family 22 member 6

multiple interactions

cyazofamid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]

NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173

G

solute carrier family 22 member 8

multiple interactions

cyazofamid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

G

solute carrier organic anion transporter family member 1B2

multiple interactions

cyazofamid inhibits the reaction [SLCO1B3 protein results in increased uptake of estrone sulfate]

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

enilconazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases expression

enilconazole results in decreased expression of ABCB11 mRNA

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 2

decreases expression

enilconazole results in decreased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

decreases expression
multiple interactions
increases expression

enilconazole results in decreased expression of ABCC3 mRNA
[enilconazole co-treated with clothianidin] results in increased expression of ABCC3 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ABCC3 mRNA
enilconazole results in increased expression of ABCC3 mRNA

PMID:29451352 PMID:33426623

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily D member 3

decreases expression

enilconazole results in decreased expression of ABCD3 mRNA

NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020

G

acyl-CoA oxidase 1

decreases expression

enilconazole results in decreased expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

adenosine kinase

increases expression

enilconazole results in increased expression of ADK mRNA

NCBI chr15:2,863,241...3,246,453
Ensembl chr15:2,863,244...3,246,510

G

aldehyde dehydrogenase 1 family, member A1

decreases expression
multiple interactions
increases expression

enilconazole results in decreased expression of ALDH1A1 mRNA
[enilconazole co-treated with clothianidin] results in increased expression of ALDH1A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ALDH1A1 mRNA
enilconazole results in increased expression of ALDH1A1 mRNA
[thiacloprid co-treated with enilconazole] results in decreased expression of ALDH1A1 mRNA

PMID:32201337 PMID:33426623

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

aldehyde dehydrogenase 2 family member

decreases expression
multiple interactions

enilconazole results in decreased expression of ALDH2 mRNA
[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein

PMID:32201337 PMID:34830855

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

anoctamin 1

decreases expression

enilconazole results in decreased expression of ANO1 mRNA

NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069

G

annexin A10

increases expression

enilconazole results in increased expression of ANXA10 mRNA

NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648

G

androgen receptor

multiple interactions
decreases expression
affects binding

Dihydrotestosterone inhibits the reaction [enilconazole results in increased activity of AR protein]; enilconazole inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; enilconazole inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; enilconazole inhibits the reaction [Metribolone results in increased activity of AR protein]
enilconazole results in decreased expression of AR mRNA
enilconazole binds to AR protein

PMID:15064155 PMID:18324785 PMID:21310686 PMID:30853599 PMID:33049310

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

arginase 1

decreases expression

enilconazole results in decreased expression of ARG1 mRNA

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

ATPase phospholipid transporting 8B1

increases expression

enilconazole results in increased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

catalase

increases expression

enilconazole results in increased expression of CAT mRNA

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 5

increases expression

enilconazole results in increased expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

carboxylesterase 2H

multiple interactions
decreases expression

[enilconazole co-treated with thiacloprid] results in increased expression of CES2 protein
enilconazole results in decreased expression of CES2 mRNA

NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830

G

CF transmembrane conductance regulator

affects binding
decreases expression

enilconazole binds to CFTR protein
enilconazole results in decreased expression of CFTR mRNA; enilconazole results in decreased expression of CFTR protein

PMID:29106682 PMID:32814239

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

catechol-O-methyltransferase

increases expression

enilconazole results in increased expression of COMT protein

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

cytochrome P450, family 11, subfamily a, polypeptide 1

affects expression

enilconazole affects the expression of CYP11A1 mRNA

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 17, subfamily a, polypeptide 1

increases expression

enilconazole results in increased expression of CYP17A1 mRNA

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity
affects secretion

enilconazole results in decreased activity of CYP19A1 protein
enilconazole affects the secretion of CYP19A1 mRNA

PMID:10806373 PMID:15554355 PMID:26141389 PMID:30853599

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases activity
increases expression
multiple interactions

enilconazole results in increased activity of CYP1A1 protein
enilconazole results in increased expression of CYP1A1 mRNA; enilconazole results in increased expression of CYP1A1 protein
enilconazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

PMID:19070657 PMID:21762035 PMID:32194361

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

affects expression
multiple interactions

enilconazole affects the expression of CYP1A2 mRNA
[clothianidin co-treated with enilconazole] results in increased expression of CYP1A2 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP1A2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression
multiple interactions

enilconazole results in increased expression of CYP1B1 mRNA
[clothianidin co-treated with enilconazole] results in increased expression of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 27, subfamily a, polypeptide 1

increases expression

enilconazole results in increased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 2, subfamily b, polypeptide 2

increases expression
multiple interactions

enilconazole results in increased expression of CYP2B2 mRNA
[enilconazole co-treated with clothianidin] results in increased expression of CYP2B2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B2 mRNA

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions
increases expression
affects expression

[enilconazole co-treated with thiacloprid] results in increased expression of CYP2B6 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B9 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B6 mRNA
enilconazole results in increased expression of CYP2B10
enilconazole affects the expression of CYP2B6 mRNA

PMID:27853109 PMID:32201337

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases expression

enilconazole results in decreased expression of CYP2C19 mRNA; enilconazole results in decreased expression of CYP2C19 protein

PMID:32194361 PMID:32201337

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
decreases expression

[clothianidin co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA
enilconazole results in decreased expression of CYP2E1 mRNA

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

affects expression
decreases activity
multiple interactions
increases expression

enilconazole affects the expression of CYP3A4 mRNA
enilconazole results in decreased activity of CYP3A4 protein
[Amiodarone co-treated with Benzoic Acid co-treated with cyproconazole co-treated with flusilazole co-treated with enilconazole co-treated with prochloraz co-treated with propiconazole co-treated with tebuconazole] results in increased expression of CYP3A4 protein; [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 mRNA; [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 protein; [enilconazole co-treated with methidathion] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A4 mRNA
enilconazole results in increased expression of CYP3A4 protein

PMID:21762035 PMID:25028461 PMID:32201337 PMID:34273450

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

multiple interactions
increases expression

[enilconazole co-treated with clothianidin] results in increased expression of CYP3A23-3A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A23-3A1 mRNA
enilconazole results in increased expression of CYP3A23-3A1 mRNA

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression
multiple interactions

enilconazole results in increased expression of CYP3A5 mRNA; enilconazole results in increased expression of CYP3A5 protein
[clothianidin co-treated with enilconazole] results in increased expression of CYP3A5 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A5 protein

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450, family 51

decreases activity

enilconazole results in decreased activity of CYP51A1 protein

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410

G

cytochrome P450 family 7 subfamily A member 1

decreases expression
multiple interactions

enilconazole results in decreased expression of CYP7A1 mRNA
[enilconazole co-treated with clothianidin] results in decreased expression of CYP7A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP7A1 mRNA
enilconazole results in decreased expression of CYP7A1 mRNA; enilconazole results in decreased expression of CYP7A1 protein

PMID:29451352 PMID:32194361 PMID:32201337 PMID:32814239 PMID:33426623

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

decreases expression

enilconazole results in decreased expression of CYP7B1 mRNA

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

cytochrome P450 family 8 subfamily B member 1

increases expression

enilconazole results in increased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

defensin alpha 3

decreases expression

enilconazole results in decreased expression of DEFA3 mRNA

NCBI chr16:70,533,436...70,535,592
Ensembl chr16:70,533,436...70,535,604

G

dynamin 1

decreases expression

enilconazole results in decreased expression of DNM1 mRNA

NCBI chr 3:15,604,782...15,648,654
Ensembl chr 3:15,604,784...15,648,538

G

elastin

decreases expression
multiple interactions

enilconazole results in decreased expression of ELN mRNA
[enilconazole co-treated with clothianidin] results in decreased expression of ELN mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of ELN mRNA

NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928

G

estrogen receptor 1

multiple interactions

enilconazole binds to and results in increased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

decreases expression
multiple interactions

enilconazole results in decreased expression of ESR2 mRNA
enilconazole binds to and results in increased activity of ESR2 protein

PMID:30853599 PMID:33049310

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

fatty acid binding protein 6

decreases expression

enilconazole results in decreased expression of FABP6 mRNA

NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282

G

Fas cell surface death receptor

increases expression

enilconazole results in increased expression of FAS mRNA

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

fibroblast growth factor 19

decreases expression
increases expression

enilconazole results in decreased expression of FGF15 mRNA
enilconazole results in increased expression of FGF15 mRNA

PMID:29451352 PMID:32814239

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

enilconazole results in decreased expression of G6PC1 mRNA

PMID:32194361 PMID:32201337

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glutathione peroxidase 1

increases expression

enilconazole results in increased expression of GPX1 mRNA

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 2

decreases expression

enilconazole results in decreased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione-disulfide reductase

increases expression

enilconazole results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione synthetase

decreases expression

enilconazole results in decreased expression of GSS mRNA

NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198

G

H2A.X variant histone

multiple interactions

[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

3-hydroxyanthranilate 3,4-dioxygenase

decreases expression

enilconazole results in decreased expression of HAAO mRNA

NCBI chr 6:10,845,235...10,864,863
Ensembl chr 6:10,845,771...10,864,877

G

3-hydroxy-3-methylglutaryl-CoA reductase

affects expression

enilconazole affects the expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

affects expression

enilconazole affects the expression of HMGCS1 mRNA

NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100

G

hydroxysteroid (17-beta) dehydrogenase 13

decreases expression

enilconazole results in decreased expression of HSD17B13 mRNA

NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

affects expression

enilconazole affects the expression of HSD3B1 mRNA

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

interferon gamma

increases expression

enilconazole results in increased expression of IFNG mRNA

PMID:27393971 PMID:32814239

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 17A

multiple interactions
increases expression

enilconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]
enilconazole results in increased expression of IL17A mRNA

PMID:22289359 PMID:32814239

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 1 alpha

increases expression

enilconazole results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression

enilconazole results in increased expression of IL1B mRNA

PMID:27393971 PMID:32814239

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases expression

enilconazole results in increased expression of IL6 mRNA

PMID:27393971 PMID:32201337 PMID:32814239

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

enilconazole results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

ketohexokinase

decreases expression

enilconazole results in decreased expression of KHK mRNA

NCBI chr 6:25,445,298...25,455,834
Ensembl chr 6:25,445,300...25,455,717

G

KLF transcription factor 4

affects expression
decreases expression

enilconazole affects the expression of KLF4 mRNA
enilconazole results in decreased expression of KLF4 mRNA

PMID:29106682 PMID:32814239

NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602

G

kyphoscoliosis peptidase

multiple interactions
decreases expression

[enilconazole co-treated with clothianidin] results in decreased expression of KY mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of KY mRNA
enilconazole results in decreased expression of KY mRNA

NCBI chr 8:103,086,959...103,126,305
Ensembl chr 8:103,086,630...103,126,024

G

lipocalin 2

increases expression

enilconazole results in increased expression of LCN2

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

luteinizing hormone subunit beta

decreases expression

enilconazole results in decreased expression of LHB protein

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

lipoprotein lipase

increases expression

enilconazole results in increased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

lymphocyte antigen 6 family member D

decreases expression

enilconazole results in decreased expression of LY6D mRNA

NCBI chr 7:106,643,225...106,644,733
Ensembl chr 7:106,643,232...106,644,733

G

mitogen-activated protein kinase 8

increases expression

enilconazole results in increased expression of MAPK8 mRNA

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

multiple EGF-like-domains 11

multiple interactions
decreases expression

[enilconazole co-treated with clothianidin] results in decreased expression of MEGF11 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of MEGF11 mRNA
enilconazole results in decreased expression of MEGF11 mRNA

NCBI chr 8:64,892,312...65,218,984
Ensembl chr 8:64,892,387...65,216,061

G

meprin A subunit beta

affects expression
decreases expression

enilconazole affects the expression of MEP1B mRNA
enilconazole results in decreased expression of MEP1B mRNA

PMID:29106682 PMID:32814239

NCBI chr18:12,366,126...12,392,840
Ensembl chr18:12,365,289...12,392,840

G

MLX interacting protein-like

decreases expression

enilconazole results in decreased expression of MLXIPL mRNA

NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112

G

membrane metallo-endopeptidase

multiple interactions
increases expression

[enilconazole co-treated with clothianidin] results in increased expression of MME mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of MME mRNA
enilconazole results in increased expression of MME mRNA

NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792

G

microsomal triglyceride transfer protein

decreases expression

enilconazole results in decreased expression of MTTP mRNA

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

mucin 1, cell surface associated

affects expression
decreases expression

enilconazole affects the expression of MUC1 mRNA
enilconazole results in decreased expression of MUC1 mRNA

PMID:29106682 PMID:32814239

NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733

G

mucin 17, cell surface associated

decreases expression

enilconazole results in decreased expression of MUC17 mRNA

NCBI chr12:19,527,251...19,536,924
Ensembl chr12:19,527,321...19,538,522

G

mucin 2, oligomeric mucus/gel-forming

affects expression
decreases expression

enilconazole affects the expression of MUC2 mRNA
enilconazole results in decreased expression of MUC2 mRNA

PMID:29106682 PMID:32814239

NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions
decreases expression

[clothianidin co-treated with enilconazole] results in decreased expression of NR0B2 mRNA
enilconazole results in decreased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group H, member 4

decreases expression
increases expression

enilconazole results in decreased expression of NR1H4 mRNA
enilconazole results in increased expression of NR1H4 mRNA

PMID:29451352 PMID:32814239

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions
increases activity

[enilconazole co-treated with methidathion] results in increased activity of NR1I2 protein; enilconazole binds to and results in increased activity of NR1I2 protein; enilconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]
enilconazole results in increased activity of NR1I2 protein

PMID:16565514 PMID:17438109 PMID:21115097 PMID:25028461 PMID:29973476 More...

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions
affects response to substance

enilconazole binds to and results in increased activity of NR1I3 protein; enilconazole inhibits the reaction [Androstane-3,17-diol binds to and results in decreased activity of NR1I3 protein]
NR1I3 protein affects the susceptibility to enilconazole

PMID:18832183 PMID:27853109

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

pyruvate dehydrogenase kinase 4

decreases expression

enilconazole results in decreased expression of PDK4 mRNA

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

patatin-like phospholipase domain containing 3

decreases expression

enilconazole results in decreased expression of PNPLA3 mRNA

NCBI chr 7:115,293,538...115,314,077
Ensembl chr 7:115,293,538...115,314,077

G

peroxisome proliferator-activated receptor gamma

multiple interactions

enilconazole binds to and results in increased activity of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

decreases expression

enilconazole results in decreased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[enilconazole binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

retinoic acid receptor, alpha

increases activity

enilconazole results in increased activity of RARA protein

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

retinoic acid receptor, gamma

increases activity

enilconazole results in increased activity of RARG protein

NCBI chr 7:133,367,833...133,390,301
Ensembl chr 7:133,367,833...133,390,177

G

resistin like beta

affects expression

enilconazole affects the expression of RETNLB mRNA

NCBI chr11:51,983,482...51,985,368
Ensembl chr11:51,983,483...51,985,368

G

regulator of cell cycle

increases expression

enilconazole results in increased expression of RGCC mRNA

NCBI chr15:54,662,483...54,675,320
Ensembl chr15:54,662,483...54,681,141

G

RAR-related orphan receptor A

multiple interactions

enilconazole binds to and results in decreased activity of RORA protein

NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931

G

stearoyl-CoA desaturase

decreases expression

enilconazole results in decreased expression of SCD mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

solute carrier family 10 member 1

decreases expression

enilconazole results in decreased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 10 member 2

increases expression

enilconazole results in increased expression of SLC10A2 mRNA

NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475

G

solute carrier family 12 member 2

decreases expression

enilconazole results in decreased expression of SLC12A2 mRNA; enilconazole results in decreased expression of SLC12A2 protein

PMID:29106682 PMID:32814239

NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440

G

solute carrier family 22 member 5

decreases expression

enilconazole results in decreased expression of SLC22A5 mRNA; enilconazole results in decreased expression of SLC22A5 protein

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

G

solute carrier family 26 member 3

decreases expression

enilconazole results in decreased expression of SLC26A3 mRNA; enilconazole results in decreased expression of SLC26A3 protein

PMID:29106682 PMID:32814239

NCBI chr 6:48,023,892...48,064,829
Ensembl chr 6:48,023,892...48,064,772

G

solute carrier family 26 member 6

decreases expression

enilconazole results in decreased expression of SLC26A6 mRNA; enilconazole results in decreased expression of SLC26A6 protein

PMID:29106682 PMID:32814239

NCBI chr 8:109,558,968...109,569,778
Ensembl chr 8:109,559,642...109,569,778

G

solute carrier family 6 member 1

multiple interactions

[enilconazole co-treated with clothianidin] results in decreased expression of SLC6A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of SLC6A1 mRNA

NCBI chr 4:147,448,961...147,482,295
Ensembl chr 4:147,466,965...147,482,293

G

solute carrier family 9 member A3

decreases expression

enilconazole results in decreased expression of SLC9A3 mRNA

PMID:29106682 PMID:32814239

NCBI chr 1:29,124,633...29,167,912
Ensembl chr 1:29,124,674...29,167,417

G

solute carrier organic anion transporter family, member 4a1

increases expression

enilconazole results in increased expression of SLCO4A1 mRNA

NCBI chr 3:167,559,177...167,578,307
Ensembl chr 3:167,559,316...167,578,305

G

superoxide dismutase 1

increases expression

enilconazole results in increased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

decreases expression

enilconazole results in decreased expression of SOD2 mRNA

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

steroidogenic acute regulatory protein

affects expression
decreases expression

enilconazole affects the expression of STAR mRNA
enilconazole results in decreased expression of STAR mRNA

PMID:30853599 PMID:36410587

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

sulfotransferase family 1B member 1

decreases expression

enilconazole results in decreased expression of SULT1B1 mRNA

NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483

G

sulfotransferase family 1C member 2A

increases expression

enilconazole results in increased expression of SULT1C2 mRNA

NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734

G

trefoil factor 3

decreases expression

enilconazole results in decreased expression of TFF3 mRNA

NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054

G

thyroid hormone receptor alpha

multiple interactions

enilconazole binds to and results in decreased activity of THRA protein

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

G

tumor necrosis factor

increases expression

enilconazole results in increased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

UDP glucuronosyltransferase family 2 member B7

decreases expression

enilconazole results in decreased expression of UGT2B7 mRNA

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604

fenamidone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression

sulforaphane inhibits the reaction [fenamidone results in increased expression of ABCA1 mRNA]

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

acyl-CoA dehydrogenase, long chain

increases expression

fenamidone results in increased expression of ACADL mRNA

NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220

G

acyl-CoA dehydrogenase short chain

increases expression

fenamidone results in increased expression of ACADS mRNA

NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898

G

acyl-CoA dehydrogenase, very long chain

increases expression

fenamidone results in increased expression of ACADVL mRNA

NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075

G

acyl-CoA synthetase bubblegum family member 1

increases expression

fenamidone results in increased expression of ACSBG1 mRNA

NCBI chr 8:54,991,294...55,047,276
Ensembl chr 8:54,991,296...55,047,391

G

actin alpha 2, smooth muscle

multiple interactions
increases expression

sulforaphane inhibits the reaction [fenamidone results in increased expression of ACTA2 mRNA]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

actinin, alpha 1

increases expression

fenamidone results in increased expression of ACTN1 mRNA

NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

increases expression

fenamidone results in increased expression of ADAMTS1 mRNA

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

ADAM metallopeptidase with thrombospondin type 1 motif, 5

increases expression

fenamidone results in increased expression of ADAMTS5 mRNA

NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205

G

ADAMTS-like 4

increases expression

fenamidone results in increased expression of ADAMTSL4 mRNA

NCBI chr 2:183,235,634...183,247,091
Ensembl chr 2:183,235,646...183,246,848

G

adenosine deaminase RNA specific B2

decreases expression

fenamidone results in decreased expression of ADARB2 mRNA

NCBI chr17:61,750,437...62,300,984
Ensembl chr17:61,756,067...62,300,831

G

adhesion G protein-coupled receptor E5

increases expression

fenamidone results in increased expression of ADGRE5 mRNA

NCBI chr19:24,397,972...24,418,648
Ensembl chr19:24,398,689...24,418,638

G

adhesion G protein-coupled receptor G6

increases expression

fenamidone results in increased expression of ADGRG6 mRNA

NCBI chr 1:8,812,889...8,954,239
Ensembl chr 1:8,812,904...8,954,123

G

adrenoceptor beta 2

increases expression

fenamidone results in increased expression of ADRB2 mRNA

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

AHNAK nucleoprotein

increases expression

fenamidone results in increased expression of AHNAK mRNA

NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926

G

ajuba LIM protein

increases expression

fenamidone results in increased expression of AJUBA mRNA

NCBI chr15:28,019,775...28,031,537
Ensembl chr15:28,019,778...28,030,021

G

aldehyde dehydrogenase 4 family, member A1

increases expression

fenamidone results in increased expression of ALDH4A1 mRNA

NCBI chr 5:151,880,002...151,905,491
Ensembl chr 5:151,830,701...151,925,345

G

angiomotin-like 1

increases expression

fenamidone results in increased expression of AMOTL1 mRNA

NCBI chr 8:11,348,651...11,467,564
Ensembl chr 8:11,353,674...11,467,573

G

angiomotin like 2

increases expression

fenamidone results in increased expression of AMOTL2 mRNA

NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910

G

angiopoietin-like 2

increases expression

fenamidone results in increased expression of ANGPTL2 mRNA

NCBI chr 3:16,517,185...16,547,024
Ensembl chr 3:16,517,420...16,548,178

G

ankyrin repeat and sterile alpha motif domain containing 1B

decreases expression

fenamidone results in decreased expression of ANKS1B mRNA

NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693

G

annexin A2

increases expression

fenamidone results in increased expression of ANXA2 mRNA

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

annexin A3

increases expression

fenamidone results in increased expression of ANXA3 mRNA

NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617

G

Rho GTPase activating protein 18

increases expression

fenamidone results in increased expression of ARHGAP18 mRNA

NCBI chr 1:18,403,531...18,637,306
Ensembl chr 1:18,403,537...18,637,256

G

actin related protein 2/3 complex, subunit 1B

increases expression

fenamidone results in increased expression of ARPC1B mRNA

NCBI chr12:9,482,176...9,495,772
Ensembl chr12:9,480,831...9,495,747

G

N-acylsphingosine amidohydrolase 1

increases expression

fenamidone results in increased expression of ASAH1 mRNA

NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233

G

argininosuccinate synthase 1

increases expression

fenamidone results in increased expression of ASS1 mRNA

NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903

G

activating transcription factor 3

increases expression

fenamidone results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 5

increases expression

fenamidone results in increased expression of ATF5 mRNA

NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707

G

atlastin GTPase 1

decreases expression

fenamidone results in decreased expression of ATL1 mRNA

NCBI chr 6:88,377,168...88,475,242
Ensembl chr 6:88,377,239...88,475,204

G

ATPase H+ transporting V0 subunit D2

increases expression

fenamidone results in increased expression of ATP6V0D2 mRNA

NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354

G

ATPase H+ transporting V0 subunit e1

increases expression

fenamidone results in increased expression of ATP6V0E mRNA

NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434

G

Axl receptor tyrosine kinase

increases expression

fenamidone results in increased expression of AXL mRNA

NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265

G

BAG cochaperone 3

increases expression

fenamidone results in increased expression of BAG3 mRNA

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

G

BCL11 transcription factor B

decreases expression

fenamidone results in decreased expression of BCL11B mRNA

NCBI chr 6:126,834,531...126,927,720
Ensembl chr 6:126,834,531...126,928,224

G

brain expressed, associated with NEDD4, 1

decreases expression

fenamidone results in decreased expression of BEAN1 mRNA

NCBI chr19:739,551...786,395
Ensembl chr19:739,551...787,537

G

basic helix-loop-helix family, member e41

increases expression

fenamidone results in increased expression of BHLHE41 mRNA

NCBI chr 4:178,834,264...178,838,618
Ensembl chr 4:178,834,271...178,838,468

G

BCL2 interacting protein 3

decreases expression

fenamidone results in decreased expression of BNIP3 mRNA

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

BTG anti-proliferation factor 2

increases expression

fenamidone results in increased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

calcium dependent secretion activator

decreases expression

fenamidone results in decreased expression of CADPS mRNA

NCBI chr15:12,289,803...12,742,786
Ensembl chr15:12,290,262...12,742,779

G

caldesmon 1

increases expression

fenamidone results in increased expression of CALD1 mRNA

NCBI chr 4:63,265,781...63,446,938
Ensembl chr 4:63,265,942...63,446,932

G

calcium/calmodulin-dependent protein kinase IV

decreases expression

fenamidone results in decreased expression of CAMK4 mRNA

NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487

G

calmodulin binding transcription activator 1

decreases expression

fenamidone results in decreased expression of CAMTA1 mRNA

NCBI chr 5:161,510,283...162,356,902
Ensembl chr 5:161,510,283...162,356,723

G

carbonic anhydrase 2

increases expression

fenamidone results in increased expression of CAR2 mRNA

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

cask-interacting protein 2

increases expression

fenamidone results in increased expression of CASKIN2 mRNA

NCBI chr10:101,027,196...101,041,429
Ensembl chr10:101,027,260...101,041,414

G

caveolae associated protein 1

increases expression

fenamidone results in increased expression of CAVIN1 mRNA

NCBI chr10:85,884,100...85,896,136
Ensembl chr10:85,889,036...85,896,120

G

carbonyl reductase 3

increases expression

fenamidone results in increased expression of CBR3 mRNA

NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875

G

coiled-coil domain containing 141

increases expression

fenamidone results in increased expression of CCDC141 mRNA

NCBI chr 3:61,948,614...62,109,968
Ensembl chr 3:61,948,646...62,110,079

G

cholecystokinin

decreases expression

fenamidone results in decreased expression of CCK mRNA

NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084

G

cellular communication network factor 1

increases expression

fenamidone results in increased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cyclin D2

increases expression

fenamidone results in increased expression of CCND2 mRNA

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin D3

increases expression

fenamidone results in increased expression of CCND3 mRNA

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

cyclin G1

increases expression

fenamidone results in increased expression of CCNG1 mRNA

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

centriole, cilia and spindle-associated protein

decreases expression

fenamidone results in decreased expression of CCSAP mRNA

NCBI chr19:51,824,954...51,843,469
Ensembl chr19:51,826,994...51,842,753

G

CD151 molecule (Raph blood group)

increases expression

fenamidone results in increased expression of CD151 mRNA

NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753

G

Cd63 molecule

increases expression

fenamidone results in increased expression of CD63 mRNA

NCBI chr 7:1,325,108...1,340,447
Ensembl chr 7:1,325,103...1,399,178

G

Cd68 molecule

increases expression

fenamidone results in increased expression of CD68 mRNA

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

CDC42 effector protein 1

increases expression

fenamidone results in increased expression of CDC42EP1 mRNA

NCBI chr 7:110,395,287...110,403,203
Ensembl chr 7:110,395,332...110,403,200

G

cyclin-dependent kinase inhibitor 1A

increases expression

fenamidone results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1C

increases expression

fenamidone results in increased expression of CDKN1C mRNA

NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048

G

CCAAT/enhancer binding protein beta

increases expression

fenamidone results in increased expression of CEBPB mRNA

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

cell migration inducing hyaluronidase 1

increases expression

fenamidone results in increased expression of CEMIP mRNA

NCBI chr 1:137,906,921...138,062,430
Ensembl chr 1:137,908,920...138,062,415

G

cerebral endothelial cell adhesion molecule

increases expression

fenamidone results in increased expression of CERCAM mRNA

NCBI chr 3:13,118,150...13,155,960
Ensembl chr 3:13,142,107...13,155,956

G

ChaC glutathione-specific gamma-glutamylcyclotransferase 1

increases expression

fenamidone results in increased expression of CHAC1 mRNA

NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526

G

carbohydrate sulfotransferase 3

increases expression

fenamidone results in increased expression of CHST3 mRNA

NCBI chr20:28,114,386...28,152,046
Ensembl chr20:28,114,404...28,121,807

G

creatine kinase B

increases expression

fenamidone results in increased expression of CKB mRNA

NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315

G

C-type lectin domain containing 7A

increases expression

fenamidone results in increased expression of CLEC7A mRNA

NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897

G

chloride intracellular channel 1

increases expression

fenamidone results in increased expression of CLIC1 mRNA

NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712

G

CLN5, intracellular trafficking protein

increases expression

fenamidone results in increased expression of CLN5 mRNA

NCBI chr15:79,893,573...79,903,438
Ensembl chr15:79,893,548...79,903,438

G

calsyntenin 3

decreases expression

fenamidone results in decreased expression of CLSTN3 mRNA

NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769

G

CKLF-like MARVEL transmembrane domain containing 3

increases expression

fenamidone results in increased expression of CMTM3 mRNA

NCBI chr19:622,563...630,721
Ensembl chr19:604,458...629,790

G

calponin 2

increases expression

fenamidone results in increased expression of CNN2 mRNA

NCBI chr 7:9,712,505...9,719,678
Ensembl chr 7:9,712,516...9,719,656

G

contactin associated protein family member 4

decreases expression

fenamidone results in decreased expression of CNTNAP4 mRNA

NCBI chr19:40,568,684...40,861,879
Ensembl chr19:40,568,684...40,854,656

G

collagen type XI alpha 1 chain

increases expression

fenamidone results in increased expression of COL11A1 mRNA

NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853

G

collagen type XII alpha 1 chain

increases expression

fenamidone results in increased expression of COL12A1 mRNA

NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686

G

collagen type IV alpha 5 chain

increases expression

fenamidone results in increased expression of COL4A5 mRNA

NCBI chr X:105,118,762...105,322,699
Ensembl chr X:105,118,820...105,322,692

G

collagen type IV alpha 6 chain

increases expression

fenamidone results in increased expression of COL4A6 mRNA

NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500

G

collagen type VIII alpha 1 chain

increases expression

fenamidone results in increased expression of COL8A1 mRNA

NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424

G

cytoplasmic polyadenylation element binding protein 1

increases expression

fenamidone results in increased expression of CPEB1 mRNA

NCBI chr 1:135,300,048...135,407,688
Ensembl chr 1:135,300,461...135,409,760

G

complexin 1

decreases expression

fenamidone results in decreased expression of CPLX1 mRNA

NCBI chr14:1,184,677...1,216,392

G

carnitine palmitoyltransferase 1A

increases expression

fenamidone results in increased expression of CPT1A mRNA

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cartilage associated protein

increases expression

fenamidone results in increased expression of CRTAP mRNA

NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631

G

colony stimulating factor 1

increases expression

fenamidone results in increased expression of CSF1 mRNA

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

cysteine and glycine-rich protein 1

increases expression

fenamidone results in increased expression of CSRP1 mRNA

NCBI chr13:47,158,171...47,179,388
Ensembl chr13:47,167,789...47,179,384

G

cystatin B

increases expression

fenamidone results in increased expression of CSTB mRNA

NCBI chr20:10,245,462...10,247,505
Ensembl chr20:10,245,462...10,247,526

G

catenin alpha 1

increases expression

fenamidone results in increased expression of CTNNA1 mRNA

NCBI chr18:26,728,246...26,860,911
Ensembl chr18:26,728,485...26,860,910

G

cathepsin D

increases expression

fenamidone results in increased expression of CTSD mRNA

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cathepsin L

increases expression

fenamidone results in increased expression of CTSL mRNA

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cathepsin Z

increases expression

fenamidone results in increased expression of CTSZ mRNA

NCBI chr 3:163,224,875...163,235,645
Ensembl chr 3:163,224,875...163,235,645

G

cytochrome b-245 alpha chain

increases expression

fenamidone results in increased expression of CYBA mRNA

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

dishevelled associated activator of morphogenesis 2

increases expression

fenamidone results in increased expression of DAAM2 mRNA

NCBI chr 9:11,428,913...11,546,982
Ensembl chr 9:11,428,724...11,545,497

G

DAB adaptor protein 2

increases expression

fenamidone results in increased expression of DAB2 mRNA

NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476

G

dicarbonyl and L-xylulose reductase

increases expression

fenamidone results in increased expression of DCXR mRNA

NCBI chr10:106,006,404...106,008,293

G

discoidin domain receptor tyrosine kinase 2

increases expression

fenamidone results in increased expression of DDR2 mRNA

NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363

G

DENN domain containing 2B

increases expression

fenamidone results in increased expression of DENND2B mRNA

NCBI chr 1:163,544,075...163,734,736
Ensembl chr 1:163,544,074...163,694,680

G

DNA fragmentation factor subunit alpha

decreases expression

fenamidone results in decreased expression of DFFA mRNA

NCBI chr 5:159,540,715...159,553,639
Ensembl chr 5:159,540,715...159,553,633

G

dynamin 3

decreases expression

fenamidone results in decreased expression of DNM3 mRNA

NCBI chr13:74,359,043...74,838,135
Ensembl chr13:74,359,213...74,838,108

G

dedicator of cyto-kinesis 1

increases expression

fenamidone results in increased expression of DOCK1 mRNA

NCBI chr 1:189,467,143...189,983,777
Ensembl chr 1:189,467,143...189,983,768

G

dipeptidyl peptidase like 10

decreases expression

fenamidone results in decreased expression of DPP10 mRNA

NCBI chr13:34,584,420...36,269,292
Ensembl chr13:34,595,868...36,269,292

G

enoyl-CoA delta isomerase 2

increases expression

fenamidone results in increased expression of ECI2 mRNA

NCBI chr17:29,850,884...29,886,781
Ensembl chr17:29,870,391...29,886,781

G

ectodysplasin A2 receptor

increases expression

fenamidone results in increased expression of EDA2R mRNA

NCBI chr X:62,224,763...62,269,333
Ensembl chr X:62,228,229...62,269,268

G

eukaryotic translation elongation factor 1 alpha 2

decreases expression

fenamidone results in decreased expression of EEF1A2 mRNA

NCBI chr 3:168,265,893...168,275,071
Ensembl chr 3:168,195,357...168,275,071

G

EGF containing fibulin extracellular matrix protein 1

increases expression

fenamidone results in increased expression of EFEMP1 mRNA

NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018

G

epidermal growth factor receptor

increases expression

fenamidone results in increased expression of EGFR mRNA

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

EH-domain containing 2

increases expression

fenamidone results in increased expression of EHD2 mRNA

NCBI chr 1:76,639,568...76,658,747
Ensembl chr 1:76,637,482...76,658,783

G

EH-domain containing 4

increases expression

fenamidone results in increased expression of EHD4 mRNA

NCBI chr 3:107,058,191...107,121,985
Ensembl chr 3:107,058,958...107,122,002

G

eukaryotic translation initiation factor 4E binding protein 1

increases expression

fenamidone results in increased expression of EIF4EBP1 mRNA

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

ELAV like RNA binding protein 2

decreases expression

fenamidone results in decreased expression of ELAVL2 mRNA

NCBI chr 5:105,960,872...106,086,463
Ensembl chr 5:105,960,875...106,109,097

G

ETS transcription factor ELK3

increases expression

fenamidone results in increased expression of ELK3 mRNA

NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084

G

elastin

increases expression

fenamidone results in increased expression of ELN mRNA

NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928

G

ELOVL fatty acid elongase 1

increases expression

fenamidone results in increased expression of ELOVL1 mRNA

NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958

G

ecto-NOX disulfide-thiol exchanger 1

decreases expression

fenamidone results in decreased expression of ENOX1 mRNA

NCBI chr15:52,517,833...53,079,752
Ensembl chr15:52,515,178...53,079,749

G

endothelial PAS domain protein 1

increases expression

fenamidone results in increased expression of EPAS1 mRNA

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

Eph receptor A2

increases expression

fenamidone results in increased expression of EPHA2 mRNA

NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117

G

epoxide hydrolase 1

increases expression

fenamidone results in increased expression of EPHX1 mRNA

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

electron transfer flavoprotein subunit beta

increases expression

fenamidone results in increased expression of ETFB mRNA

NCBI chr 1:93,851,908...93,866,072
Ensembl chr 1:93,851,858...93,866,068

G

ETS proto-oncogene 1, transcription factor

increases expression

fenamidone results in increased expression of ETS1 mRNA

NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010

G

EvC ciliary complex subunit 1

increases expression

fenamidone results in increased expression of EVC mRNA

NCBI chr14:73,456,181...73,498,955
Ensembl chr14:73,456,222...73,498,099

G

coagulation factor II (thrombin) receptor

increases expression

fenamidone results in increased expression of F2R mRNA

NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870

G

coagulation factor III, tissue factor

increases expression

fenamidone results in increased expression of F3 mRNA

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

Fas apoptotic inhibitory molecule 2

decreases expression

fenamidone results in decreased expression of FAIM2 mRNA

NCBI chr 7:130,632,368...130,659,353
Ensembl chr 7:130,633,348...130,659,168

G

FAT atypical cadherin 1

increases expression

fenamidone results in increased expression of FAT1 mRNA

NCBI chr16:47,177,253...47,296,261
Ensembl chr16:47,177,248...47,296,107

G

fibrillin 1

increases expression

fenamidone results in increased expression of FBN1 mRNA

NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889

G

f-box protein 9

decreases expression

fenamidone results in decreased expression of FBXO9 mRNA

NCBI chr 8:78,958,482...78,984,015
Ensembl chr 8:78,958,483...78,983,949

G

Fibroblast growth factor receptor 1

increases expression

fenamidone results in increased expression of FGFR1 mRNA

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

fibroblast growth factor receptor 3

increases expression

fenamidone results in increased expression of FGFR3 mRNA

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

FKBP prolyl isomerase 10

increases expression

fenamidone results in increased expression of FKBP10 mRNA

NCBI chr10:85,345,434...85,357,998
Ensembl chr10:85,346,126...85,427,330

G

FKBP prolyl isomerase 9

increases expression

fenamidone results in increased expression of FKBP9 mRNA

NCBI chr 4:86,106,256...86,156,723
Ensembl chr 4:86,106,282...86,156,721

G

filamin A

increases expression

fenamidone results in increased expression of FLNA mRNA

NCBI chr X:152,007,758...152,034,266
Ensembl chr X:152,007,758...152,031,052

G

filamin B

increases expression

fenamidone results in increased expression of FLNB mRNA

NCBI chr15:16,961,999...17,095,059
Ensembl chr15:16,962,003...17,095,006

G

filamin C

increases expression

fenamidone results in increased expression of FLNC mRNA

NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844

G

fibronectin 1

increases expression

fenamidone results in increased expression of FN1 mRNA

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

FERM domain containing 8

increases expression

fenamidone results in increased expression of FRMD8 mRNA

NCBI chr 1:203,143,216...203,163,868
Ensembl chr 1:203,143,218...203,163,870

G

frizzled class receptor 7

increases expression

fenamidone results in increased expression of FZD7 mRNA

NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781

G

glutamate decarboxylase 1

decreases expression

fenamidone results in decreased expression of GAD1 mRNA

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

glutamate decarboxylase 2

decreases expression

fenamidone results in decreased expression of GAD2 mRNA

NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155

G

growth arrest and DNA-damage-inducible, alpha

increases expression

fenamidone results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

polypeptide N-acetylgalactosaminyltransferase 9

decreases expression

fenamidone results in decreased expression of GALNT9 mRNA

NCBI chr12:46,050,395...46,128,626
Ensembl chr12:46,050,413...46,128,578

G

growth differentiation factor 15

increases expression

fenamidone results in increased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

gap junction protein, delta 2

decreases expression

fenamidone results in decreased expression of GJD2 mRNA

NCBI chr 3:100,771,450...100,776,134
Ensembl chr 3:100,772,062...100,775,061

G

glycosylated lysosomal membrane protein

increases expression

fenamidone results in increased expression of GLMP mRNA

NCBI chr 2:173,794,273...173,797,863
Ensembl chr 2:173,794,255...173,799,960

G

glycine receptor, alpha 2

decreases expression

fenamidone results in decreased expression of GLRA2 mRNA

NCBI chr X:29,020,377...29,241,666
Ensembl chr X:29,020,557...29,241,666

G

glutaminase

decreases expression

fenamidone results in decreased expression of GLS mRNA

NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900

G

glycolipid transfer protein

increases expression

fenamidone results in increased expression of GLTP mRNA

NCBI chr12:41,907,168...41,927,321
Ensembl chr12:41,907,144...41,927,319

G

G protein subunit gamma 12

increases expression

fenamidone results in increased expression of GNG12 mRNA

NCBI chr 4:96,011,118...96,134,767
Ensembl chr 4:96,010,952...96,134,712

G

glycoprotein nmb

increases expression

fenamidone results in increased expression of GPNMB mRNA

NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367

G

G protein-coupled receptor 22

decreases expression

fenamidone results in decreased expression of GPR22 mRNA

NCBI chr 6:48,309,619...48,317,864
Ensembl chr 6:48,310,505...48,317,486

G

G-protein coupled receptor 88

decreases expression

fenamidone results in decreased expression of GPR88 mRNA

NCBI chr 2:204,191,443...204,199,576
Ensembl chr 2:204,191,427...204,199,733

G

glutathione peroxidase 1

increases expression

fenamidone results in increased expression of GPX1 mRNA

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutamate ionotropic receptor kainate type subunit 3

decreases expression

fenamidone results in decreased expression of GRIK3 mRNA

NCBI chr 5:137,767,865...137,989,617
Ensembl chr 5:137,767,865...137,984,307

G

granulin precursor

increases expression

fenamidone results in increased expression of GRN mRNA

NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775

G

glutathione synthetase

increases expression

fenamidone results in increased expression of GSS mRNA

NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198

G

glutathione S-transferase mu 1

multiple interactions
increases expression

sulforaphane inhibits the reaction [fenamidone results in increased expression of GSTM1 mRNA]

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

G-2 and S-phase expressed 1

increases expression

fenamidone results in increased expression of GTSE1 mRNA

NCBI chr 7:116,949,997...116,966,826
Ensembl chr 7:116,950,053...116,966,806

G

glucoside xylosyltransferase 2

increases expression

fenamidone results in increased expression of GXYLT2 mRNA

NCBI chr 4:133,347,230...133,449,708
Ensembl chr 4:133,347,499...133,449,454

G

3-hydroxyacyl-CoA dehydratase 4

increases expression

fenamidone results in increased expression of HACD4 mRNA

NCBI chr 5:102,887,597...102,915,376
Ensembl chr 5:102,887,588...102,915,338

G

hydroxyacyl-CoA dehydrogenase

increases expression

fenamidone results in increased expression of HADH mRNA

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

hyaluronan and proteoglycan link protein 1

decreases expression

fenamidone results in decreased expression of HAPLN1 mRNA

NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777

G

heparin-binding EGF-like growth factor

increases expression

fenamidone results in increased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

heme oxygenase 1

multiple interactions
increases expression

sulforaphane inhibits the reaction [fenamidone results in increased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heparan sulfate-glucosamine 3-sulfotransferase 2

decreases expression

fenamidone results in decreased expression of HS3ST2 mRNA

NCBI chr 1:175,956,161...176,077,400
Ensembl chr 1:175,956,157...176,077,399

G

heparan sulfate proteoglycan 2

increases expression

fenamidone results in increased expression of HSPG2 mRNA

NCBI chr 5:149,677,437...149,778,594
Ensembl chr 5:149,677,476...149,778,594

G

hyaluronidase 1

increases expression

fenamidone results in increased expression of HYAL1 mRNA

NCBI chr 8:108,250,668...108,254,519
Ensembl chr 8:108,250,667...108,260,210

G

intercellular adhesion molecule 1

increases expression

fenamidone results in increased expression of ICAM1 mRNA

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

immediate early response 3

increases expression

fenamidone results in increased expression of IER3 mRNA

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

IFI30, lysosomal thiol reductase

increases expression

fenamidone results in increased expression of IFI30 mRNA

NCBI chr16:18,675,590...18,679,655
Ensembl chr16:18,675,613...18,681,175

G

interferon induced transmembrane protein 2

increases expression

fenamidone results in increased expression of IFITM2 mRNA

NCBI chr 1:196,051,539...196,052,719
Ensembl chr 1:196,051,537...196,052,741

G

immunoglobulin superfamily, DCC subclass, member 4

increases expression

fenamidone results in increased expression of IGDCC4 mRNA

NCBI chr 8:65,621,893...65,657,651
Ensembl chr 8:65,621,897...65,657,648

G

insulin-like growth factor binding protein 3

increases expression

fenamidone results in increased expression of IGFBP3 mRNA

NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083

G

insulin-like growth factor binding protein-like 1

increases expression

fenamidone results in increased expression of IGFBPL1 mRNA

NCBI chr 5:60,076,428...60,091,833
Ensembl chr 5:60,076,429...60,091,833

G

interleukin 1 receptor accessory protein

increases expression

fenamidone results in increased expression of IL1RAP mRNA

NCBI chr11:74,062,999...74,199,530
Ensembl chr11:74,070,304...74,199,530

G

inverted formin 2

increases expression

fenamidone results in increased expression of INF2 mRNA

NCBI chr 6:131,649,162...131,675,944
Ensembl chr 6:131,649,211...131,675,941

G

interaction protein for cytohesin exchange factors 1

decreases expression

fenamidone results in decreased expression of IPCEF1 mRNA

NCBI chr 1:43,237,903...43,451,735
Ensembl chr 1:43,269,202...43,427,969

G

interleukin-1 receptor-associated kinase 1

increases expression

fenamidone results in increased expression of IRAK1 mRNA

NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521

G

integrin subunit alpha 3

increases expression

fenamidone results in increased expression of ITGA3 mRNA

NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118

G

integrin subunit alpha 5

increases expression

fenamidone results in increased expression of ITGA5 mRNA

NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837

G

integrin subunit alpha 6

increases expression

fenamidone results in increased expression of ITGA6 mRNA

NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428

G

integrin subunit alpha 7

increases expression

fenamidone results in increased expression of ITGA7 mRNA

NCBI chr 7:1,360,125...1,388,886
Ensembl chr 7:1,359,940...1,388,450

G

integrin subunit alpha V

increases expression

fenamidone results in increased expression of ITGAV mRNA

NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639

G

integrin subunit beta 1

increases expression

fenamidone results in increased expression of ITGB1 mRNA

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

ITPR interacting domain containing 2

increases expression

fenamidone results in increased expression of ITPRID2 mRNA

NCBI chr 3:64,536,707...64,573,978
Ensembl chr 3:64,536,707...64,573,978

G

KN motif and ankyrin repeat domains 4

increases expression

fenamidone results in increased expression of KANK4 mRNA

NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555

G

potassium voltage-gated channel subfamily A member 1

decreases expression

fenamidone results in decreased expression of KCNA1 mRNA

NCBI chr 4:159,464,223...159,472,905
Ensembl chr 4:159,464,188...159,472,682

G

potassium voltage-gated channel subfamily C member 2

decreases expression

fenamidone results in decreased expression of KCNC2 mRNA

NCBI chr 7:47,700,035...47,883,979
Ensembl chr 7:47,700,288...47,883,968

G

potassium voltage-gated channel subfamily H member 3

decreases expression
multiple interactions

fenamidone results in decreased expression of KCNH3 mRNA
sulforaphane inhibits the reaction [fenamidone results in decreased expression of KCNH3 mRNA]

NCBI chr 7:130,365,593...130,383,859
Ensembl chr 7:130,366,011...130,383,855

G

potassium voltage-gated channel modifier subfamily V member 1

decreases expression

fenamidone results in decreased expression of KCNV1 mRNA

NCBI chr 7:76,260,695...76,269,170
Ensembl chr 7:76,260,695...76,269,170

G

kinesin family member 1C

increases expression

fenamidone results in increased expression of KIF1C mRNA

NCBI chr10:55,414,412...55,444,587
Ensembl chr10:55,415,900...55,443,545

G

kinesin family member 5A

decreases expression

fenamidone results in decreased expression of KIF5A mRNA

NCBI chr 7:63,051,894...63,089,024
Ensembl chr 7:63,049,424...63,092,858

G

kirre like nephrin family adhesion molecule 1

increases expression

fenamidone results in increased expression of KIRREL1 mRNA

NCBI chr 2:172,521,644...172,615,057
Ensembl chr 2:172,525,245...172,615,299

G

KLF transcription factor 3

increases expression

fenamidone results in increased expression of KLF3 mRNA

NCBI chr14:43,474,767...43,505,801
Ensembl chr14:43,474,767...43,497,209

G

KLF transcription factor 4

increases expression

fenamidone results in increased expression of KLF4 mRNA

NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602

G

laminin subunit alpha 5

increases expression

fenamidone results in increased expression of LAMA5 mRNA

NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451

G

laminin subunit beta 1

increases expression

fenamidone results in increased expression of LAMB1 mRNA

NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585

G

laminin subunit beta 2

increases expression

fenamidone results in increased expression of LAMB2 mRNA

NCBI chr 8:109,178,367...109,190,552
Ensembl chr 8:109,178,409...109,190,549

G

laminin subunit gamma 1

increases expression

fenamidone results in increased expression of LAMC1 mRNA

NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492

G

large tumor suppressor kinase 2

increases expression

fenamidone results in increased expression of LATS2 mRNA

NCBI chr15:31,825,068...31,877,193
Ensembl chr15:31,825,092...31,877,220

G

galectin 1

increases expression

fenamidone results in increased expression of LGALS1 mRNA

NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345

G

galectin 3

increases expression

fenamidone results in increased expression of LGALS3 mRNA

NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025

G

leucine-rich, glioma inactivated 1

decreases expression

fenamidone results in decreased expression of LGI1 mRNA

NCBI chr 1:236,043,269...236,084,617
Ensembl chr 1:236,042,954...236,084,616

G

LHFPL tetraspan subfamily member 6

increases expression

fenamidone results in increased expression of LHFPL6 mRNA

NCBI chr 2:137,126,485...137,324,442
Ensembl chr 2:137,126,509...137,324,443

G

LIF, interleukin 6 family cytokine

increases expression

fenamidone results in increased expression of LIF mRNA

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

LIM domain and actin binding 1

multiple interactions
increases expression

sulforaphane inhibits the reaction [fenamidone results in increased expression of LIMA1 mRNA]

NCBI chr 7:130,901,717...131,001,512
Ensembl chr 7:130,901,717...131,001,473

G

lipase A, lysosomal acid type

increases expression

fenamidone results in increased expression of LIPA mRNA

NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633

G

lipopolysaccharide-induced TNF factor

increases expression

fenamidone results in increased expression of LITAF mRNA

NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763

G

leiomodin 1

increases expression

fenamidone results in increased expression of LMOD1 mRNA

NCBI chr13:46,754,048...46,796,186
Ensembl chr13:46,754,033...46,794,900

G

LIM domain containing preferred translocation partner in lipoma

increases expression

fenamidone results in increased expression of LPP mRNA

NCBI chr11:75,787,326...76,426,646
Ensembl chr11:75,797,078...76,422,597

G

LDL receptor related protein 2

increases expression

fenamidone results in increased expression of LRP2 mRNA

NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708

G

LDL receptor related protein 5

increases expression

fenamidone results in increased expression of LRP5 mRNA

NCBI chr 1:200,814,247...200,917,581
Ensembl chr 1:200,814,250...200,917,581

G

leucine-rich repeat kinase 1

increases expression

fenamidone results in increased expression of LRRK1 mRNA

NCBI chr 1:119,844,360...119,972,885
Ensembl chr 1:119,845,146...119,979,734

G

leucine-rich repeat kinase 2

increases expression

fenamidone results in increased expression of LRRK2 mRNA

NCBI chr 7:122,826,696...122,987,711
Ensembl chr 7:122,826,696...122,987,703

G

LSM11, U7 small nuclear RNA associated

decreases expression

fenamidone results in decreased expression of LSM11 mRNA

NCBI chr10:30,367,841...30,385,956
Ensembl chr10:30,370,727...30,385,944

G

leucine zipper tumor suppressor 1

decreases expression

fenamidone results in decreased expression of LZTS1 mRNA

NCBI chr16:20,542,756...20,598,204
Ensembl chr16:20,542,809...20,598,203

G

MAF bZIP transcription factor F

increases expression

fenamidone results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

mannosidase, alpha, class 2B, member 1

increases expression

fenamidone results in increased expression of MAN2B1 mRNA

NCBI chr19:23,055,092...23,074,398
Ensembl chr19:23,055,097...23,074,389

G

mannosidase, alpha, class 2B, member 2

increases expression

fenamidone results in increased expression of MAN2B2 mRNA

NCBI chr14:73,969,079...73,994,089
Ensembl chr14:73,969,003...74,004,281

G

mitogen-activated protein kinase kinase kinase 20

increases expression

fenamidone results in increased expression of MAP3K20 mRNA

NCBI chr 3:57,130,539...57,289,943
Ensembl chr 3:57,130,551...57,289,626

G

MAPK activated protein kinase 3

increases expression

fenamidone results in increased expression of MAPKAPK3 mRNA

NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568

G

minichromosome maintenance complex component 2

increases expression

fenamidone results in increased expression of MCM2 mRNA

NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847

G

midkine

increases expression

fenamidone results in increased expression of MDK mRNA

NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130

G

moesin

increases expression

fenamidone results in increased expression of MSN mRNA

NCBI chr X:60,996,043...61,064,011
Ensembl chr X:60,995,951...61,065,628

G

methionine sulfoxide reductase B3

increases expression

fenamidone results in increased expression of MSRB3 mRNA

NCBI chr 7:56,260,985...56,426,004
Ensembl chr 7:56,303,308...56,425,496

G

methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1

increases expression

fenamidone results in increased expression of MTHFD1 mRNA

NCBI chr 6:94,977,862...95,045,375
Ensembl chr 6:94,977,862...95,045,372

G

MYB proto-oncogene like 1

increases expression

fenamidone results in increased expression of MYBL1 mRNA

NCBI chr 5:9,582,905...9,618,179
Ensembl chr 5:9,582,934...9,618,183

G

myosin, heavy chain 9

increases expression

fenamidone results in increased expression of MYH9 mRNA

NCBI chr 7:109,343,718...109,424,457
Ensembl chr 7:109,343,706...109,424,457

G

myosin light chain 12A

increases expression

fenamidone results in increased expression of MYL12A mRNA

NCBI chr 9:110,891,970...110,899,655
Ensembl chr 9:110,873,959...110,916,580

G

myosin light chain 9

increases expression

fenamidone results in increased expression of MYL9 mRNA

NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333

G

myoferlin

increases expression

fenamidone results in increased expression of MYOF mRNA

NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334

G

Ngfi-A binding protein 2

increases expression

fenamidone results in increased expression of NAB2 mRNA

NCBI chr 7:63,497,589...63,504,105
Ensembl chr 7:63,497,589...63,503,989

G

NACC family member 2

increases expression

fenamidone results in increased expression of NACC2 mRNA

NCBI chr 3:8,879,952...8,946,660
Ensembl chr 3:8,883,065...8,946,660

G

nucleosome assembly protein 1-like 2

decreases expression

fenamidone results in decreased expression of NAP1L2 mRNA

NCBI chr X:68,174,051...68,176,449
Ensembl chr X:68,173,987...68,176,666

G

NSF attachment protein beta

decreases expression

fenamidone results in decreased expression of NAPB mRNA

NCBI chr 3:136,132,248...136,179,280
Ensembl chr 3:136,133,428...136,179,345

G

nuclear prelamin A recognition factor

decreases expression

fenamidone results in decreased expression of NARF mRNA

NCBI chr10:106,519,508...106,537,494
Ensembl chr10:106,519,444...106,537,486

G

NIMA-related kinase 6

increases expression

fenamidone results in increased expression of NEK6 mRNA

NCBI chr 3:22,284,269...22,356,302
Ensembl chr 3:22,284,279...22,395,990

G

nestin

increases expression

fenamidone results in increased expression of NES mRNA

NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777

G

neuropilin and tolloid like 1

decreases expression

fenamidone results in decreased expression of NETO1 mRNA

NCBI chr18:79,635,633...79,753,913
Ensembl chr18:79,635,633...79,749,030

G

nuclear factor kappa B subunit 2

increases expression

fenamidone results in increased expression of NFKB2 mRNA

NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213

G

nerve growth factor receptor

increases expression

fenamidone results in increased expression of TNFRSF10B mRNA

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

nicotinamide nucleotide transhydrogenase

increases expression

fenamidone results in increased expression of NNT mRNA

NCBI chr 2:51,411,413...51,505,125
Ensembl chr 2:51,411,413...51,504,823

G

notch receptor 1

increases expression

fenamidone results in increased expression of NOTCH1 mRNA

NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531

G

notch receptor 3

increases expression

fenamidone results in increased expression of NOTCH3 mRNA

NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025

G

natriuretic peptide receptor 2

increases expression

fenamidone results in increased expression of NPR2 mRNA

NCBI chr 5:57,883,171...57,901,590
Ensembl chr 5:57,883,171...57,901,580

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

fenamidone results in increased expression of NQO1 mRNA
sulforaphane inhibits the reaction [fenamidone results in increased expression of NQO1 mRNA]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

neuregulin 1

increases expression

fenamidone results in increased expression of NRG1 mRNA

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

neurexin 3

decreases expression

fenamidone results in decreased expression of NRXN3 mRNA

NCBI chr 6:107,641,760...109,272,849
Ensembl chr 6:107,641,780...109,272,044

G

NUAK family kinase 2

increases expression

fenamidone results in increased expression of NUAK2 mRNA

NCBI chr13:43,753,454...43,770,604
Ensembl chr13:43,753,832...43,770,604

G

nucleoporin 93

increases expression

fenamidone results in increased expression of NUP93 mRNA

NCBI chr19:10,684,214...10,788,009
Ensembl chr19:10,682,075...10,788,026

G

neurexophilin 1

decreases expression

fenamidone results in decreased expression of NXPH1 mRNA

NCBI chr 4:36,998,068...37,311,135
Ensembl chr 4:36,997,669...37,311,132

G

neurexophilin 2

decreases expression

fenamidone results in decreased expression of NXPH2 mRNA

NCBI chr 3:5,986,175...5,988,525
Ensembl chr 3:5,756,621...5,987,008

G

osteoclast stimulating factor 1

increases expression

fenamidone results in increased expression of OSTF1 mRNA

NCBI chr 1:216,002,037...216,049,226
Ensembl chr 1:216,002,044...216,049,221

G

purinergic receptor P2Y2

increases expression

fenamidone results in increased expression of P2RY2 mRNA

NCBI chr 1:155,352,050...155,367,423
Ensembl chr 1:155,351,165...155,367,632

G

palladin, cytoskeletal associated protein

increases expression

fenamidone results in increased expression of PALLD mRNA

NCBI chr16:28,228,006...28,621,349
Ensembl chr16:27,981,354...28,621,337

G

poly (ADP-ribose) polymerase family, member 3

increases expression

fenamidone results in increased expression of PARP3 mRNA

NCBI chr 8:107,111,010...107,117,073
Ensembl chr 8:107,111,012...107,116,782

G

protocadherin 19

decreases expression

fenamidone results in decreased expression of PCDH19 mRNA

NCBI chr X:96,767,686...96,873,477
Ensembl chr X:96,771,947...96,873,524

G

phosphoenolpyruvate carboxykinase 2 (mitochondrial)

increases expression

fenamidone results in increased expression of PCK2 mRNA

NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283

G

phosphate cytidylyltransferase 1B, choline

decreases expression

fenamidone results in decreased expression of PCYT1B mRNA

NCBI chr X:58,378,090...58,471,623
Ensembl chr X:58,378,116...58,468,935

G

platelet derived growth factor receptor beta

increases expression

fenamidone results in increased expression of PDGFRB mRNA

NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843

G

PDZ and LIM domain 2

increases expression

fenamidone results in increased expression of PDLIM2 mRNA

NCBI chr15:45,235,421...45,250,187
Ensembl chr15:45,237,477...45,249,242

G

PDZ and LIM domain 5

increases expression

fenamidone results in increased expression of PDLIM5 mRNA

NCBI chr 2:230,952,251...231,120,329
Ensembl chr 2:230,952,248...231,120,275

G

phosphoglucomutase 2-like 1

decreases expression

fenamidone results in decreased expression of PGM2L1 mRNA

NCBI chr 1:154,571,410...154,620,901
Ensembl chr 1:154,571,766...154,620,902

G

phosphoglycerate dehydrogenase

increases expression

fenamidone results in increased expression of PHGDH mRNA

NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944

G

pleckstrin homology-like domain, family A, member 3

increases expression

fenamidone results in increased expression of PHLDA3 mRNA

NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335

G

pleckstrin homology-like domain, family B, member 2

increases expression

fenamidone results in increased expression of PHLDB2 mRNA

NCBI chr11:54,859,173...55,078,212
Ensembl chr11:54,859,135...55,078,467

G

phytanoyl-CoA 2-hydroxylase

increases expression

fenamidone results in increased expression of PHYH mRNA

NCBI chr17:73,329,461...73,346,359
Ensembl chr17:73,329,082...73,346,409

G

piezo-type mechanosensitive ion channel component 1

increases expression

fenamidone results in increased expression of PIEZO1 mRNA

NCBI chr19:50,544,580...50,606,812
Ensembl chr19:50,544,582...50,606,501

G

plasminogen activator, urokinase

increases expression

fenamidone results in increased expression of PLAU mRNA

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

phospholipase C beta 3

increases expression

fenamidone results in increased expression of PLCB3 mRNA

NCBI chr 1:204,143,257...204,160,384
Ensembl chr 1:204,144,956...204,160,228

G

pleckstrin homology domain containing A7

increases expression

fenamidone results in increased expression of PLEKHA7 mRNA

NCBI chr 1:170,364,524...170,547,843
Ensembl chr 1:170,365,135...170,547,775

G

pleckstrin homology and RhoGEF domain containing G2

increases expression

fenamidone results in increased expression of PLEKHG2 mRNA

NCBI chr 1:83,651,902...83,665,063
Ensembl chr 1:83,647,748...83,665,063

G

pleckstrin homology domain containing O2

increases expression

fenamidone results in increased expression of PLEKHO2 mRNA

NCBI chr 8:66,079,106...66,105,283
Ensembl chr 8:66,078,448...66,105,266

G

plexin B2

increases expression

fenamidone results in increased expression of PLXNB2 mRNA

NCBI chr 7:120,232,276...120,258,385
Ensembl chr 7:120,232,331...120,258,330

G

PML nuclear body scaffold

increases expression

fenamidone results in increased expression of PML mRNA

NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971

G

protein O-glucosyltransferase 3

increases expression

fenamidone results in increased expression of POGLUT3 mRNA

NCBI chr 8:53,777,614...53,795,404
Ensembl chr 8:53,777,785...53,795,399

G

protein phosphatase, Mg2+/Mn2+ dependent, 1E

decreases expression

fenamidone results in decreased expression of PPM1E mRNA

NCBI chr10:72,051,643...72,187,439
Ensembl chr10:72,055,208...72,187,282

G

protein kinase C, delta

increases expression

fenamidone results in increased expression of PRKCD mRNA

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

protein kinase C, gamma

decreases expression

fenamidone results in decreased expression of PRKCG mRNA

NCBI chr 1:65,832,851...65,860,676
Ensembl chr 1:65,832,855...65,859,384

G

protein kinase D1

increases expression

fenamidone results in increased expression of PRKD1 mRNA

NCBI chr 6:67,725,193...68,039,002
Ensembl chr 6:67,725,905...68,039,042

G

prion like protein doppel

increases expression

fenamidone results in increased expression of PRND mRNA

NCBI chr 3:119,213,462...119,218,742
Ensembl chr 3:119,213,429...119,218,745

G

serine protease 23

increases expression

fenamidone results in increased expression of PRSS23 mRNA

NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091

G

protein tyrosine phosphatase, non-receptor type 13

increases expression

fenamidone results in increased expression of PTPN13 mRNA

NCBI chr14:6,108,202...6,282,619
Ensembl chr14:6,108,211...6,282,563

G

protein tyrosine phosphatase, non-receptor type 14

increases expression

fenamidone results in increased expression of PTPN14 mRNA

NCBI chr13:101,268,258...101,420,508
Ensembl chr13:101,268,416...101,414,088

G

protein tyrosine phosphatase, non-receptor type 21

increases expression

fenamidone results in increased expression of PTPN21 mRNA

NCBI chr 6:117,933,066...117,998,095
Ensembl chr 6:117,933,066...117,998,095

G

PTTG1 regulator of sister chromatid separation, securin

increases expression

fenamidone results in increased expression of PTTG1 mRNA

NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837

G

pentraxin 3

increases expression

fenamidone results in increased expression of PTX3 mRNA

NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323

G

RAB3B, member RAS oncogene family

decreases expression

fenamidone results in decreased expression of RAB3B mRNA

NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401

G

RE1-silencing transcription factor

increases expression

fenamidone results in increased expression of REST mRNA

NCBI chr14:30,859,109...30,879,828
Ensembl chr14:30,862,553...30,894,354

G

regulator of G-protein signaling 7 binding protein

decreases expression

fenamidone results in decreased expression of RGS7BP mRNA

NCBI chr 2:36,133,944...36,231,505
Ensembl chr 2:36,139,201...36,231,505

G

rhomboid 5 homolog 2

increases expression

fenamidone results in increased expression of RHBDF2 mRNA

NCBI chr10:101,833,157...101,860,283
Ensembl chr10:101,833,157...101,860,283

G

ras homolog family member C

increases expression

fenamidone results in increased expression of RHOC mRNA

NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306

G

ras homolog family member D

increases expression

fenamidone results in increased expression of RHOD mRNA

NCBI chr 1:201,708,699...201,724,405
Ensembl chr 1:201,708,699...201,722,632

G

ras homolog family member G

increases expression

fenamidone results in increased expression of RHOG mRNA

NCBI chr 1:156,618,713...156,630,710
Ensembl chr 1:156,615,349...156,631,257

G

ribosomal modification protein rimK-like family member A

decreases expression

fenamidone results in decreased expression of RIMKLA mRNA

NCBI chr 5:133,072,179...133,098,840
Ensembl chr 5:133,073,960...133,098,792

G

rabphilin 3A

decreases expression

fenamidone results in decreased expression of RPH3A mRNA

NCBI chr12:35,542,389...35,618,901
Ensembl chr12:35,542,728...35,617,592

G

sterile alpha motif domain containing 4A

increases expression

fenamidone results in increased expression of SAMD4 mRNA

NCBI chr15:20,135,994...20,352,131
Ensembl chr15:20,134,377...20,348,380

G

sarcosine dehydrogenase

increases expression

fenamidone results in increased expression of SARDH mRNA

NCBI chr 3:10,510,553...10,575,342
Ensembl chr 3:10,510,553...10,573,874

G

scavenger receptor class F, member 2

increases expression

fenamidone results in increased expression of SCARF2 mRNA

NCBI chr11:83,175,956...83,187,415
Ensembl chr11:83,175,963...83,187,348

G

syndecan 1

increases expression

fenamidone results in increased expression of SDC1 mRNA

NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264

G

serpin family F member 1

increases expression

fenamidone results in increased expression of SERPINF1 mRNA

NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646

G

serpin family H member 1

increases expression

fenamidone results in increased expression of SERPINH1 mRNA

NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801

G

serpin family I member 1

decreases expression

fenamidone results in decreased expression of SERPINI1 mRNA

NCBI chr 2:160,346,403...160,433,135
Ensembl chr 2:160,346,758...160,433,135

G

sestrin 2

increases expression

fenamidone results in increased expression of SESN2 mRNA

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

sphingomyelin synthase 2

increases expression

fenamidone results in increased expression of SGMS2 mRNA

NCBI chr 2:219,889,809...219,967,704
Ensembl chr 2:219,893,572...219,967,546

G

SH3 and multiple ankyrin repeat domains 1

decreases expression

fenamidone results in decreased expression of SHANK1 mRNA

NCBI chr 1:94,807,879...94,857,356
Ensembl chr 1:94,808,276...94,855,824

G

SHC adaptor protein 1

increases expression

fenamidone results in increased expression of SHC1 mRNA

NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536

G

solute carrier family 12 member 4

increases expression

fenamidone results in increased expression of SLC12A4 mRNA

NCBI chr19:33,838,418...33,860,369
Ensembl chr19:33,838,419...33,860,331

G

solute carrier family 12 member 5

decreases expression

fenamidone results in decreased expression of SLC12A5 mRNA

NCBI chr 3:153,696,517...153,735,801
Ensembl chr 3:153,696,517...153,735,765

G

solute carrier family 12 member 7

increases expression

fenamidone results in increased expression of SLC12A7 mRNA

NCBI chr 1:29,472,692...29,554,246
Ensembl chr 1:29,472,692...29,554,302

G

solute carrier family 32 member 1

decreases expression

fenamidone results in decreased expression of SLC32A1 mRNA

NCBI chr 3:147,267,373...147,271,842
Ensembl chr 3:147,267,373...147,271,844

G

solute carrier family 4 member 2

increases expression

fenamidone results in increased expression of SLC4A2 mRNA

NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965

G

solute carrier family 66 member 3

increases expression

fenamidone results in increased expression of SLC66A3 mRNA

NCBI chr 6:39,774,801...39,786,554
Ensembl chr 6:39,774,808...39,786,303

G

solute carrier family 8 member A3

decreases expression

fenamidone results in decreased expression of SLC8A3 mRNA

NCBI chr 6:100,874,359...101,007,989
Ensembl chr 6:100,874,369...101,007,508

G

small integral membrane protein 10 like 2A

decreases expression

fenamidone results in decreased expression of SMIM10L2A mRNA

NCBI chr X:134,151,325...134,154,647

G

sphingomyelin phosphodiesterase 3

decreases expression

fenamidone results in decreased expression of SMPD3 mRNA

NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749

G

sorting nexin 33

increases expression

fenamidone results in increased expression of SNX33 mRNA

NCBI chr 8:57,315,861...57,328,522
Ensembl chr 8:57,317,161...57,327,538

G

sorbin and SH3 domain containing 3

increases expression

fenamidone results in increased expression of SORBS3 mRNA

NCBI chr15:45,252,921...45,284,758
Ensembl chr15:45,253,379...45,284,758

G

sortilin related receptor 1

increases expression

fenamidone results in increased expression of SORL1 mRNA

NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513

G

secreted protein acidic and cysteine rich

increases expression

fenamidone results in increased expression of SPARC mRNA

NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396

G

SPARC/osteonectin, cwcv and kazal like domains proteoglycan 3

decreases expression

fenamidone results in decreased expression of SPOCK3 mRNA

NCBI chr16:26,382,895...26,815,943
Ensembl chr16:26,383,383...26,815,205

G

shadow of prion protein

decreases expression

fenamidone results in decreased expression of SPRN mRNA

NCBI chr 1:194,944,602...194,948,448
Ensembl chr 1:194,943,826...194,948,460

G

sulfiredoxin 1

increases expression

fenamidone results in increased expression of SRXN1 mRNA

NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448

G

scavenger receptor cysteine rich family member with 5 domains

increases expression

fenamidone results in increased expression of SSC5D mRNA

NCBI chr 1:68,891,942...68,910,462
Ensembl chr 1:68,891,949...68,909,743

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3

decreases expression

fenamidone results in decreased expression of ST8SIA3 mRNA

NCBI chr18:57,754,349...57,760,839
Ensembl chr18:57,754,347...57,760,839

G

serine/threonine kinase 17b

increases expression

fenamidone results in increased expression of STK17B mRNA

NCBI chr 9:55,307,485...55,338,085
Ensembl chr 9:55,307,668...55,338,031

G

stonin 1

increases expression

fenamidone results in increased expression of STON1 mRNA

NCBI chr 6:5,843,186...5,892,557
Ensembl chr 6:5,843,185...5,892,449

G

Sad1 and UNC84 domain containing 2

increases expression

fenamidone results in increased expression of SUN2 mRNA

NCBI chr 7:111,275,374...111,292,565
Ensembl chr 7:111,275,380...111,292,553

G

synaptic vesicle glycoprotein 2b

decreases expression

fenamidone results in decreased expression of SV2B mRNA

NCBI chr 1:128,978,471...129,152,479
Ensembl chr 1:128,978,473...129,152,479

G

supervillin

increases expression

fenamidone results in increased expression of SVIL mRNA

NCBI chr17:52,648,502...52,844,114
Ensembl chr17:52,648,502...52,793,404

G

switching B-cell complex subunit SWAP70

increases expression

fenamidone results in increased expression of SWAP70 mRNA

NCBI chr 1:164,267,588...164,328,796
Ensembl chr 1:164,267,609...164,328,794

G

synapse defective Rho GTPase homolog 1

increases expression

fenamidone results in increased expression of SYDE1 mRNA

NCBI chr 7:11,032,931...11,038,917
Ensembl chr 7:11,032,898...11,039,869

G

synapsin I

decreases expression

fenamidone results in decreased expression of SYN1 mRNA

NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396

G

syncoilin, intermediate filament protein

increases expression

fenamidone results in increased expression of SYNC mRNA

NCBI chr 5:141,631,837...141,656,184
Ensembl chr 5:141,632,367...141,688,659

G

synaptotagmin 1

decreases expression

fenamidone results in decreased expression of SYT1 mRNA

NCBI chr 7:43,813,204...44,358,020
Ensembl chr 7:43,815,785...44,357,803

G

transgelin

increases expression

fenamidone results in increased expression of TAGLN mRNA

NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668

G

T-cell immune regulator 1, ATPase H+ transporting V0 subunit A3

increases expression

fenamidone results in increased expression of TCIRG1 mRNA

NCBI chr 1:201,127,034...201,138,787
Ensembl chr 1:201,127,034...201,138,742

G

TEA domain transcription factor 1

increases expression

fenamidone results in increased expression of TEAD1 mRNA

NCBI chr 1:166,791,900...167,010,591
Ensembl chr 1:166,792,628...167,003,369

G

TEA domain transcription factor 2

increases expression

fenamidone results in increased expression of TEAD2 mRNA

NCBI chr 1:95,702,366...95,719,186
Ensembl chr 1:95,703,005...95,719,186

G

terminal nucleotidyltransferase 5B

increases expression

fenamidone results in increased expression of TENT5B mRNA

NCBI chr 5:145,695,358...145,702,668
Ensembl chr 5:145,695,362...145,706,073

G

transforming growth factor, beta 2

increases expression

fenamidone results in increased expression of TGFB2 mRNA

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

G

transforming growth factor, beta 3

increases expression

fenamidone results in increased expression of TGFB3 mRNA

NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564

G

thrombospondin 1

increases expression

fenamidone results in increased expression of THBS1 mRNA

NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440

G

TIMP metallopeptidase inhibitor 3

increases expression

fenamidone results in increased expression of TIMP3 mRNA

NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839

G

tubulointerstitial nephritis antigen-like 1

increases expression

fenamidone results in increased expression of TINAGL1 mRNA

NCBI chr 5:142,513,710...142,523,730
Ensembl chr 5:142,513,714...142,523,720

G

tight junction associated protein 1

increases expression

fenamidone results in increased expression of TJAP1 mRNA

NCBI chr 9:14,701,418...14,725,623
Ensembl chr 9:14,701,468...14,725,751

G

talin 1

increases expression

fenamidone results in increased expression of TLN1 mRNA

NCBI chr 5:57,787,670...57,817,900
Ensembl chr 5:57,787,943...57,817,900

G

transmembrane BAX inhibitor motif containing 1

increases expression

fenamidone results in increased expression of TMBIM1 mRNA

NCBI chr 9:75,871,835...75,889,366
Ensembl chr 9:75,871,835...75,889,069

G

transmembrane protein 178A

decreases expression

fenamidone results in decreased expression of TMEM178 mRNA

NCBI chr 6:14,004,629...14,063,677
Ensembl chr 6:14,004,630...14,063,549

G

tenascin C

increases expression

fenamidone results in increased expression of TNC mRNA

NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624

G

TNF receptor superfamily member 12A

increases expression

fenamidone results in increased expression of TNFRSF12A mRNA

NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045

G

TNF receptor superfamily member 1A

increases expression

fenamidone results in increased expression of TNFRSF1A mRNA

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

G

tensin 1

increases expression

fenamidone results in increased expression of TNS1 mRNA

NCBI chr 9:75,491,886...75,702,853
Ensembl chr 9:75,495,814...75,703,225

G

tensin 3

increases expression

fenamidone results in increased expression of TNS3 mRNA

NCBI chr14:83,173,649...83,405,671
Ensembl chr14:83,173,649...83,405,998

G

tropomyosin 4

increases expression

fenamidone results in increased expression of TPM4 mRNA

NCBI chr16:17,684,415...17,698,456
Ensembl chr16:17,683,195...17,705,984

G

tripeptidyl peptidase 1

increases expression

fenamidone results in increased expression of TPP1 mRNA

NCBI chr 1:160,097,984...160,104,108
Ensembl chr 1:160,096,833...160,104,129

G

tweety family member 2

increases expression

fenamidone results in increased expression of TTYH2 mRNA

NCBI chr10:99,709,063...99,753,449
Ensembl chr10:99,709,007...99,753,444

G

tubulin, alpha 4A

decreases expression

fenamidone results in decreased expression of TUBA4A mRNA

NCBI chr 9:76,709,617...76,714,327
Ensembl chr 9:76,709,614...76,713,918

G

tubulin, beta 6 class V

increases expression

fenamidone results in increased expression of TUBB6 mRNA

NCBI chr18:60,943,394...60,953,031
Ensembl chr18:60,943,375...60,954,418

G

tuftelin 1

increases expression

fenamidone results in increased expression of TUFT1 mRNA

NCBI chr 2:182,259,457...182,306,296
Ensembl chr 2:182,260,398...182,306,192

G

thioredoxin reductase 1

increases expression

fenamidone results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

UDP-N-acetylglucosamine pyrophosphorylase 1 like 1

increases expression

fenamidone results in increased expression of UAP1L1 mRNA

NCBI chr 3:8,172,335...8,180,505
Ensembl chr 3:8,173,216...8,180,443

G

utrophin

increases expression

fenamidone results in increased expression of UTRN mRNA

NCBI chr 1:6,720,854...7,224,313
Ensembl chr 1:6,722,594...7,224,313

G

vasorin

increases expression

fenamidone results in increased expression of VASN mRNA

NCBI chr10:10,917,750...10,928,259
Ensembl chr10:10,917,605...10,928,357

G

vinculin

increases expression

fenamidone results in increased expression of VCL mRNA

NCBI chr15:3,265,776...3,355,586
Ensembl chr15:3,265,815...3,355,606

G

vestigial-like family member 3

increases expression

fenamidone results in increased expression of VGLL3 mRNA

NCBI chr11:3,642,993...3,692,590
Ensembl chr11:3,643,069...3,689,140

G

vimentin

increases expression

fenamidone results in increased expression of VIM mRNA

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

visinin-like 1

decreases expression

fenamidone results in decreased expression of VSNL1 mRNA

NCBI chr 6:34,038,641...34,159,479
Ensembl chr 6:34,038,642...34,159,479

G

WASP family member 2

increases expression

fenamidone results in increased expression of WASF2 mRNA

NCBI chr 5:145,336,817...145,402,041
Ensembl chr 5:145,336,842...145,399,242

G

Wnt family member 9A

increases expression

fenamidone results in increased expression of WNT9A mRNA

NCBI chr10:44,094,140...44,121,134
Ensembl chr10:44,094,140...44,121,133

G

XK related 4

decreases expression

fenamidone results in decreased expression of XKR4 mRNA

NCBI chr 5:15,896,818...16,297,733
Ensembl chr 5:15,895,863...16,282,962

G

Yip1 interacting factor homolog A, membrane trafficking protein

increases expression

fenamidone results in increased expression of YIF1A mRNA

NCBI chr 1:202,394,923...202,399,125
Ensembl chr 1:202,394,897...202,399,427

G

yippee-like 1

decreases expression

fenamidone results in decreased expression of YPEL1 mRNA

NCBI chr11:83,921,799...83,936,409

G

zinc finger and BTB domain containing 7B

increases expression

fenamidone results in increased expression of ZBTB7B mRNA

NCBI chr 2:174,795,831...174,811,980
Ensembl chr 2:174,797,453...174,814,236

G

zinc finger protein 36, C3H type-like 2

increases expression

fenamidone results in increased expression of ZFP36L2 mRNA

NCBI chr 6:10,490,032...10,494,073
Ensembl chr 6:10,490,032...10,494,064

G

zyxin

increases expression

fenamidone results in increased expression of ZYX mRNA

NCBI chr 4:71,236,767...71,246,553
Ensembl chr 4:71,237,451...71,246,553

iprodione

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

iprodione binds to and results in increased activity of AHR protein

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aldehyde dehydrogenase 2 family member

multiple interactions

[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

annexin A10

increases expression

iprodione results in increased expression of ANXA10 mRNA

NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648

G

androgen receptor

multiple interactions
affects binding

[iprodione binds to and results in decreased activity of AR protein] inhibits the reaction [Metribolone binds to AR protein]; iprodione inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; iprodione inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]
iprodione binds to AR protein

PMID:19564212 PMID:33049310

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

iprodione results in decreased expression of BCL2 protein
Chlorpyrifos promotes the reaction [iprodione results in decreased expression of BCL2 protein]; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of BCL2 protein]

PMID:33586219 PMID:34060014

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

increases expression
multiple interactions

iprodione results in increased expression of CASP3 protein
Chlorpyrifos promotes the reaction [iprodione results in increased expression of CASP3 protein]; iprodione promotes the reaction [Chlorpyrifos results in increased expression of CASP3 protein]

PMID:33586219 PMID:34060014

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cadherin 1

multiple interactions

[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in decreased expression of CDH1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in decreased expression of CDH1 protein

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

claudin 11

increases expression
multiple interactions

iprodione results in increased expression of CLDN11 protein
[carbendazim co-treated with iprodione] results in decreased expression of CLDN11 protein

NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050

G

cytochrome P450, family 19, subfamily a, polypeptide 1

increases activity

iprodione results in increased activity of CYP19A1 protein

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

iprodione results in increased expression of CYP1A1 mRNA; iprodione results in increased expression of CYP1A1 protein

PMID:16696176 PMID:32194361

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases expression

iprodione results in decreased expression of CYP2C19 protein

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

iprodione results in decreased expression of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

DNA-damage inducible transcript 3

increases expression

iprodione results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

estrogen receptor 1

multiple interactions

iprodione binds to and results in increased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

iprodione binds to and results in increased activity of ESR2 protein

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

iprodione results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

follicle stimulating hormone subunit beta

multiple interactions
decreases expression

Chlorpyrifos inhibits the reaction [iprodione results in decreased expression of FSHB protein]; iprodione inhibits the reaction [Chlorpyrifos results in decreased expression of FSHB protein]; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of FSHB protein]

PMID:33586219 PMID:34060014

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

growth arrest and DNA-damage-inducible, alpha

increases expression

iprodione results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

gap junction protein, alpha 1

multiple interactions

[carbendazim co-treated with iprodione] results in decreased expression of GJA1 protein

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

glutathione S-transferase alpha 2

increases expression

iprodione results in increased expression of GSTA2 mRNA

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

H2A.X variant histone

multiple interactions

[fludioxonil co-treated with cyprodinil co-treated with procymidone co-treated with iprodione co-treated with cyhalothrin] results in increased phosphorylation of H2AX protein; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in increased expression of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased expression of H2AX protein

PMID:22389207 PMID:34503147 PMID:34830855

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

hydroxysteroid (17-beta) dehydrogenase 3

multiple interactions
decreases expression

[Chlorpyrifos co-treated with iprodione] results in decreased expression of HSD17B3 mRNA; [iprodione co-treated with Chlorpyrifos] results in decreased expression of HSD17B3 mRNA
iprodione results in decreased expression of HSD17B3 mRNA

PMID:33586219 PMID:34060014

NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554

G

heat shock protein family A (Hsp70) member 5

increases expression

iprodione results in increased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

luteinizing hormone subunit beta

multiple interactions
decreases expression

Chlorpyrifos inhibits the reaction [iprodione results in decreased expression of LHB protein]; iprodione inhibits the reaction [Chlorpyrifos results in decreased expression of LHB protein]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased activity of NR1I2 protein; iprodione binds to and results in increased activity of NR1I2 protein

PMID:25028461 PMID:33049310

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 5, group A, member 1

decreases expression
multiple interactions

iprodione results in decreased expression of NR5A1 mRNA
[iprodione co-treated with Chlorpyrifos] results in decreased expression of NR5A1 mRNA; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of NR5A1 mRNA]

PMID:33586219 PMID:34060014

NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328

G

peroxisome proliferator-activated receptor gamma

increases activity
multiple interactions

iprodione results in increased activity of PPARG protein
iprodione binds to and results in increased activity of PPARG protein

PMID:20143881 PMID:33049310

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

decreases expression
multiple interactions

iprodione results in decreased expression of PPARGC1A mRNA
Chlorpyrifos promotes the reaction [iprodione results in decreased expression of PPARGC1A mRNA]; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of PPARGC1A mRNA]

PMID:33586219 PMID:34060014

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

sirtuin 1

multiple interactions
decreases expression

[iprodione co-treated with Chlorpyrifos] results in decreased expression of SIRT1 mRNA; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of SIRT1 mRNA]
iprodione results in decreased expression of SIRT1 mRNA

PMID:33586219 PMID:34060014

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

stathmin 1

increases expression

iprodione results in increased expression of STMN1 mRNA

NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154

G

telomerase reverse transcriptase

multiple interactions
decreases expression

[Chlorpyrifos co-treated with iprodione] results in decreased expression of TERT mRNA; [iprodione co-treated with Chlorpyrifos] results in decreased expression of TERT mRNA
iprodione results in decreased expression of TERT mRNA

PMID:33586219 PMID:34060014

NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561

G

thyroid hormone receptor alpha

multiple interactions

iprodione binds to and results in increased activity of THRA protein

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

G

thyroid hormone receptor beta

multiple interactions

iprodione binds to and results in increased activity of THRB protein

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

G

tumor necrosis factor

multiple interactions

Acetylcysteine inhibits the reaction [iprodione inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; iprodione inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53 binding protein 1

multiple interactions

[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] affects the expression of TP53BP1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] affects the expression of TP53BP1 protein

NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822

prochloraz

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCB11 mRNA

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

increases expression
multiple interactions

prochloraz results in increased expression of ABCB1A mRNA; prochloraz results in increased expression of ABCB1A protein
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCB1A mRNA

PMID:27028005 PMID:29038839 PMID:33150952

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

multiple interactions

prochloraz results in increased expression of and results in increased activity of ABCB1B protein

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily C member 2

increases expression
multiple interactions

prochloraz results in increased expression of ABCC2 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions
increases expression

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCC3 mRNA
prochloraz results in increased expression of ABCC3 protein

PMID:29038839 PMID:33150952

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 2

decreases expression

prochloraz results in decreased expression of ABCG2 mRNA

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

aconitase 1

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACO1 mRNA

NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391

G

acyl-CoA thioesterase 3

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACOT3 mRNA

NCBI chr 6:103,682,518...103,688,735
Ensembl chr 6:103,682,596...103,688,427
Ensembl chr 6:103,682,596...103,688,427

G

acyl-CoA thioesterase 9

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACOT9 mRNA

NCBI chr X:40,073,197...40,123,573
Ensembl chr X:40,064,810...40,123,559

G

actinin, alpha 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ACTN1 mRNA

NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251

G

activin A receptor type 2B

decreases expression
multiple interactions

prochloraz results in decreased expression of SCGB2A2 mRNA
prochloraz inhibits the reaction [Testosterone Propionate results in increased expression of SCGB2A2 mRNA]

PMID:12377983 PMID:15519604 PMID:16375936

NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458

G

alcohol dehydrogenase 4 (class II), pi polypeptide

increases expression

prochloraz results in increased expression of ADH4 mRNA

NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591

G

adiponectin, C1Q and collagen domain containing

decreases expression

prochloraz results in decreased expression of ADIPOQ mRNA

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

aryl hydrocarbon receptor

multiple interactions
increases expression

prochloraz binds to and results in increased activity of AHR protein
prochloraz results in increased expression of AHR mRNA

PMID:14636698 PMID:18835618 PMID:25182419

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aldehyde dehydrogenase 1 family, member A1

increases expression
multiple interactions

prochloraz results in increased expression of ALDH1A1 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ALDH1A1 mRNA

PMID:25182419 PMID:29038839

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

annexin A10

increases expression

prochloraz results in increased expression of ANXA10 mRNA

NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648

G

apurinic/apyrimidinic endodeoxyribonuclease 1

multiple interactions
increases expression

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of APEX1 mRNA
prochloraz results in increased expression of APEX1 mRNA

NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785

G

androgen receptor

decreases activity
multiple interactions
affects binding

prochloraz results in decreased activity of AR protein
prochloraz binds to and results in decreased activity of AR protein; prochloraz inhibits the reaction [Metribolone binds to AR protein]; prochloraz inhibits the reaction [Metribolone results in increased expression of AR mRNA]
prochloraz binds to AR protein
[procymidone co-treated with prochloraz co-treated with vinclozolin] inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; [propiconazole co-treated with prochloraz co-treated with tebuconazole] inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; [propiconazole co-treated with prochloraz] inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; [tebuconazole co-treated with prochloraz] inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; Dihydrotestosterone inhibits the reaction [prochloraz results in increased activity of AR protein]; prochloraz binds to and results in decreased activity of AR protein; prochloraz inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; prochloraz inhibits the reaction [Dihydrotestosterone affects the localization of and results in increased phosphorylation of AR protein]; prochloraz inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; prochloraz inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; prochloraz inhibits the reaction [Metribolone results in increased activity of AR protein]

PMID:14687758 PMID:15064155 PMID:15519604 PMID:15673607 PMID:18315717 More...

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

arginase 1

decreases expression

prochloraz results in decreased expression of ARG1 mRNA

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

aryl hydrocarbon receptor nuclear translocator

affects expression

prochloraz affects the expression of ARNT mRNA

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

asparagine synthetase (glutamine-hydrolyzing)

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ASNS mRNA

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423

G

ATM serine/threonine kinase

increases expression

prochloraz results in increased expression of ATM mRNA

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase phospholipid transporting 8B1

increases expression

prochloraz results in increased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

beta-secretase 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of BACE1 mRNA

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

beta-secretase 2

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of BACE2 mRNA

NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546

G

BCL2 associated X, apoptosis regulator

multiple interactions

prochloraz inhibits the reaction [Testosterone results in increased expression of BAX mRNA]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl2-like 1

increases expression

prochloraz results in increased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

Bcl2-like 11

increases expression

prochloraz results in increased expression of BCL2L11 mRNA

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

brain-derived neurotrophic factor

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of BDNF mRNA

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

bassoon (presynaptic cytomatrix protein)

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of BSN mRNA

NCBI chr 8:108,784,849...108,875,819
Ensembl chr 8:108,788,542...108,875,819

G

calcium voltage-gated channel subunit alpha1 A

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1A mRNA

NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225

G

calcium voltage-gated channel subunit alpha1 B

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1B mRNA

NCBI chr 3:7,380,892...7,546,104
Ensembl chr 3:7,380,922...7,546,091

G

calcium voltage-gated channel subunit alpha1 C

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1C mRNA

NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648

G

calcium voltage-gated channel subunit alpha1 D

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1D mRNA

NCBI chr16:5,227,157...5,521,163
Ensembl chr16:5,228,306...5,668,215

G

calcium voltage-gated channel subunit alpha1 G

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1G mRNA

NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752

G

calcium voltage-gated channel subunit alpha1 I

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNA1I mRNA

NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688

G

calcium voltage-gated channel auxiliary subunit alpha2delta 3

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CACNA2D3 mRNA

NCBI chr16:4,098,439...4,912,498
Ensembl chr16:4,098,445...4,912,351

G

calcium voltage-gated channel auxiliary subunit beta 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNB1 mRNA

NCBI chr10:82,998,182...83,018,838
Ensembl chr10:82,998,182...83,018,694

G

calcium voltage-gated channel auxiliary subunit beta 3

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNB3 mRNA

NCBI chr 7:129,784,799...129,797,074
Ensembl chr 7:129,783,674...129,797,074

G

calcium voltage-gated channel auxiliary subunit gamma 2

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG2 mRNA

NCBI chr 7:109,572,838...109,698,516
Ensembl chr 7:109,574,459...109,697,227

G

calcium voltage-gated channel auxiliary subunit gamma 6

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG6 mRNA

NCBI chr 1:65,732,910...65,747,377
Ensembl chr 1:65,732,632...65,747,341

G

calcium voltage-gated channel auxiliary subunit gamma 7

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNG7 mRNA

NCBI chr 1:65,800,059...65,831,246
Ensembl chr 1:65,800,355...65,831,006

G

cell adhesion molecule 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CADM1 mRNA

NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833

G

calcium/calmodulin-dependent protein kinase II beta

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CAMK2B mRNA

NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994

G

calcium/calmodulin-dependent protein kinase II gamma

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CAMK2G mRNA

NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050

G

CD36 molecule

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

CD44 molecule

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CD44 mRNA

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

Cd81 molecule

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CD81 mRNA

NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
decreases expression

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in decreased expression of CDKN1A mRNA
prochloraz results in decreased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

carboxylesterase 2C

increases expression
multiple interactions

prochloraz results in increased expression of CES2C mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CES2C mRNA

PMID:25182419 PMID:29038839

NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790

G

chromogranin A

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CHGA mRNA

NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398

G

carnitine palmitoyltransferase 2

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CPT2 mRNA

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

prochloraz results in decreased expression of CYP11A1 mRNA

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 11, subfamily b, polypeptide 2

decreases expression
multiple interactions

prochloraz results in decreased expression of CYP11B1 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in decreased expression of CYP11B1 mRNA

PMID:19733639 PMID:28454766

NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases activity
multiple interactions
increases expression
decreases expression

prochloraz results in decreased activity of CYP17A1 protein
[prochloraz results in decreased activity of CYP17A1 protein] which results in decreased chemical synthesis of Testosterone
prochloraz results in increased expression of CYP17A1 mRNA; prochloraz results in increased expression of CYP17A1 protein
prochloraz results in decreased expression of and results in decreased activity of CYP17A1 protein
prochloraz results in decreased expression of CYP17A1 mRNA

PMID:16375936 PMID:17234647 PMID:17369198 PMID:19733639 PMID:25324206

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity
increases activity
multiple interactions
increases expression

prochloraz results in decreased activity of CYP19A1 protein
prochloraz results in increased activity of CYP19A1 protein
[prochloraz co-treated with Chlorpyrifos co-treated with triflusulfuron-methyl] results in increased expression of CYP19A1 mRNA; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased expression of CYP19A1 mRNA
prochloraz results in increased expression of CYP19A1 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CYP19A1 mRNA

PMID:10806373 PMID:11884232 PMID:15554355 PMID:16996190 PMID:20087668 More...

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases activity
increases expression
multiple interactions

prochloraz results in increased activity of CYP1A1 protein
prochloraz results in increased expression of CYP1A1 mRNA; prochloraz results in increased expression of CYP1A1 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [prochloraz results in increased expression of CYP1A1 mRNA]; [NR1I2 protein co-treated with NR1I3 protein co-treated with prochloraz] results in increased expression of CYP1A1 mRNA
[prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased activity of CYP1A1 protein; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased expression of CYP1A1 mRNA

PMID:20035023 PMID:21784029 PMID:25182419 PMID:25233012 PMID:25765474 More...

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

prochloraz results in increased expression of CYP1A2 mRNA; prochloraz results in increased expression of CYP1A2 protein

PMID:21784029 PMID:25182419 PMID:33150952

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression

prochloraz results in increased expression of CYP1B1 mRNA; prochloraz results in increased expression of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily b, polypeptide 1

increases activity
increases expression
multiple interactions

prochloraz results in increased activity of CYP2B1 protein
prochloraz results in increased expression of CYP2B1 mRNA
[prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased activity of CYP2B1 protein; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased expression of CYP2B1 mRNA

PMID:25182419 PMID:29038839

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 15

increases expression

prochloraz results in increased expression of CYP2B15 mRNA

NCBI chr 1:82,094,188...82,106,492
Ensembl chr 1:82,094,180...82,106,492

G

cytochrome P450, family 2, subfamily b, polypeptide 2

increases expression
multiple interactions

prochloraz results in increased expression of CYP2B2 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CYP2B2 mRNA

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions
increases expression

[NR1I2 protein co-treated with NR1I3 protein] affects the reaction [prochloraz results in increased expression of CYP2B10 protein]
prochloraz results in increased expression of CYP2B6 mRNA; prochloraz results in increased expression of CYP2B6 protein
prochloraz results in increased expression of CYP2B10 mRNA; prochloraz results in increased expression of CYP2B10 protein

PMID:28058446 PMID:33150952

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, subfamily 2, polypeptide 11

increases expression

prochloraz results in increased expression of CYP2C11 protein

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily c, polypeptide 13

increases expression

prochloraz results in increased expression of CYP2C13 protein

NCBI chr 1:238,786,764...238,867,195
Ensembl chr 1:238,786,765...238,867,191

G

cytochrome P450, family 2, subfamily c, polypeptide 24

increases expression

prochloraz results in increased expression of CYP2C55 protein

NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases expression
increases expression

prochloraz results in decreased expression of CYP2C19 protein
prochloraz results in increased expression of CYP2C29 protein

PMID:32194361 PMID:33150952

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

decreases expression

prochloraz results in decreased expression of CYP2D6 mRNA

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases expression

prochloraz results in decreased expression of CYP2E1 mRNA

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 2, subfamily j, polypeptide 4

decreases expression

prochloraz results in decreased expression of CYP2J2 mRNA

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

cytochrome P450, family 2, subfamily u, polypeptide 1

decreases expression

prochloraz results in decreased expression of CYP2U1 mRNA

NCBI chr 2:219,849,403...219,866,959
Ensembl chr 2:219,849,407...219,866,882

G

cytochrome P450, family 3, subfamily a, polypeptide 18

increases expression

prochloraz results in increased expression of CYP3A18 protein

NCBI chr12:8,880,509...8,930,382
Ensembl chr12:8,880,528...8,930,381

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases expression

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CYP3A2 mRNA
prochloraz results in increased expression of CYP3A4 protein
[Amiodarone co-treated with Benzoic Acid co-treated with cyproconazole co-treated with flusilazole co-treated with enilconazole co-treated with prochloraz co-treated with propiconazole co-treated with tebuconazole] results in increased expression of CYP3A4 protein

PMID:29038839 PMID:33150952 PMID:34273450

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression
increases activity
multiple interactions

prochloraz results in increased expression of CYP3A23-3A1 mRNA
prochloraz results in increased activity of CYP3A23-3A1 protein
[prochloraz co-treated with cyproconazole co-treated with epoxiconazole] results in increased expression of CYP3A23-3A1 mRNA; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased activity of CYP3A23-3A1 protein

PMID:25182419 PMID:29038839

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression

prochloraz results in increased expression of CYP3A9 protein

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450, family 51

decreases activity

prochloraz results in decreased activity of CYP51A1 protein

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

prochloraz results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

DCC netrin 1 receptor

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DCC mRNA

NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740

G

discs large MAGUK scaffold protein 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DLG1 mRNA

NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689

G

discs large MAGUK scaffold protein 4

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of DLG4 mRNA; [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DLG4 mRNA

NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153

G

DLG associated protein 3

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DLGAP3 mRNA

NCBI chr 5:139,491,972...139,562,625
Ensembl chr 5:139,492,947...139,562,625

G

DLG associated protein 4

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DLGAP4 mRNA

NCBI chr 3:145,124,189...145,271,791
Ensembl chr 3:145,175,479...145,270,490

G

double C2 domain alpha

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DOC2A mRNA

NCBI chr 1:181,457,415...181,462,528
Ensembl chr 1:181,458,390...181,462,030

G

dipeptidyl peptidase like 10

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DPP10 mRNA

NCBI chr13:34,584,420...36,269,292
Ensembl chr13:34,595,868...36,269,292

G

dipeptidyl peptidase like 6

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DPP6 mRNA

NCBI chr 4:7,589,386...8,508,666
Ensembl chr 4:7,591,009...8,508,532

G

dihydropyrimidine dehydrogenase

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DPYD mRNA

NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982

G

epidermal growth factor

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGF mRNA

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of EHHADH mRNA

NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of EIF2AK3 mRNA

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

E1A binding protein p300

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of EP300 mRNA

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

erb-b2 receptor tyrosine kinase 3

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA

NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB4 mRNA; [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB4 mRNA

NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595

G

ERCC excision repair 1, endonuclease non-catalytic subunit

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ERCC1 mRNA

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

ERCC excision repair 2, TFIIH core complex helicase subunit

increases expression

prochloraz results in increased expression of ERCC2 mRNA

NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102

G

estrogen receptor 1

multiple interactions
decreases expression

Fulvestrant inhibits the reaction [prochloraz results in decreased expression of ESR1 mRNA]; prochloraz binds to and results in increased activity of ESR1 protein; prochloraz inhibits the reaction [Estradiol results in decreased expression of ESR1 mRNA]
prochloraz results in decreased expression of ESR1 mRNA; prochloraz results in decreased expression of ESR1 protein

PMID:15130599 PMID:15261991 PMID:33049310

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions
decreases expression

Fulvestrant inhibits the reaction [prochloraz results in decreased expression of ESR2 mRNA]; prochloraz binds to and results in increased activity of ESR2 protein; prochloraz promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]

PMID:15130599 PMID:15261991 PMID:33049310

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

fatty acid binding protein 4

decreases expression

prochloraz results in decreased expression of FABP4 mRNA

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

Fas cell surface death receptor

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of FAS mRNA

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

fragile X messenger ribonucleoprotein 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FMR1 mRNA

NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050

G

FYN proto-oncogene, Src family tyrosine kinase

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FYN mRNA

NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

prochloraz results in decreased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

gamma-aminobutyric acid type A receptor subunit alpha 4

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GABRA4 mRNA

NCBI chr14:36,590,782...36,667,724
Ensembl chr14:36,590,782...36,665,844

G

gamma-aminobutyric acid type A receptor subunit beta1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GABRB1 mRNA

NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948

G

glial cell derived neurotrophic factor

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GDNF mRNA

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

gamma-glutamyltransferase 1

increases expression

prochloraz results in increased expression of GGT1 mRNA

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

glutaminase

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GLS mRNA

NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900

G

glutamate ionotropic receptor AMPA type subunit 2

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA

NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510

G

glutamate ionotropic receptor AMPA type subunit 4

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA4 mRNA

NCBI chr 8:1,562,118...2,035,035
Ensembl chr 8:1,562,119...2,034,979

G

glutamate ionotropic receptor kainate type subunit 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of GRIK1 mRNA

NCBI chr11:27,169,739...27,571,131
Ensembl chr11:27,169,740...27,570,645

G

glutamate ionotropic receptor kainate type subunit 2

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIK2 mRNA

NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375

G

glutamate ionotropic receptor NMDA type subunit 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of GRIN1 mRNA

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of GRIN2B mRNA

NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279

G

glutamate receptor interacting protein 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIP1 mRNA

NCBI chr 7:54,934,856...55,592,274
Ensembl chr 7:54,934,250...55,592,273

G

glutathione-disulfide reductase

increases expression

prochloraz results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 5

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of GSTA5 mRNA

NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression

prochloraz results in increased expression of HERPUD1 mRNA

NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424

G

hes family bHLH transcription factor 6

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of HES6 mRNA

NCBI chr 9:92,001,849...92,003,562
Ensembl chr 9:92,001,841...92,003,559

G

hydroxysteroid (17-beta) dehydrogenase 10

decreases expression

prochloraz results in decreased expression of HSD17B10 protein

NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488

G

hydroxysteroid (17-beta) dehydrogenase 2

increases expression

prochloraz results in increased expression of HSD17B2 mRNA

NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2

decreases activity
decreases expression

prochloraz results in decreased activity of HSD3B2 protein
prochloraz results in decreased expression of HSD3B2 mRNA

NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852

G

heat shock protein family B (small) member 8

increases expression
multiple interactions

prochloraz results in increased expression of HSPB8 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of HSPB8 mRNA

NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185

G

insulin-like growth factor 1

decreases expression

prochloraz results in decreased expression of IGF1 mRNA

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 2 receptor

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of IGF2R mRNA

NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501

G

interleukin 1 receptor accessory protein-like 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of IL1RAPL1 mRNA

NCBI chr X:51,371,969...52,876,726
Ensembl chr X:51,378,215...52,876,772

G

kallikrein 1-related peptidase C10

multiple interactions

prochloraz inhibits the reaction [Dihydrotestosterone results in increased secretion of KLK3 protein]

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

leptin

decreases expression

prochloraz results in decreased expression of LEP mRNA

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

luteinizing hormone subunit beta

increases expression

prochloraz results in increased expression of LHB protein

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

leucine rich repeat containing 7

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of LRRC7 mRNA

NCBI chr 2:247,146,616...247,634,945
Ensembl chr 2:247,147,752...247,634,547

G

lymphocyte antigen 6 family member D

increases expression

prochloraz results in increased expression of LY6D mRNA

NCBI chr 7:106,643,225...106,644,733
Ensembl chr 7:106,643,232...106,644,733

G

membrane associated guanylate kinase, WW and PDZ domain containing 2

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of MAGI2 mRNA

NCBI chr 4:14,386,389...15,870,036
Ensembl chr 4:14,386,399...15,870,240

G

mannosidase beta

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MANBA mRNA

NCBI chr 2:223,910,432...224,002,988
Ensembl chr 2:223,910,432...224,002,983

G

mitogen activated protein kinase 1

multiple interactions

prochloraz inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

prochloraz inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MAM domain containing glycosylphosphatidylinositol anchor 2

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of MDGA2 mRNA

NCBI chr 6:84,746,422...85,608,640
Ensembl chr 6:84,761,941...85,608,126

G

MDM2 proto-oncogene

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MDM2 mRNA

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

microsomal glutathione S-transferase 2

increases expression

prochloraz results in increased expression of MGST2 mRNA

NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:135,693,557...135,715,828

G

mutL homolog 1

increases expression

prochloraz results in increased expression of MLH1 mRNA

NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617

G

MAX dimerization protein MLX

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MLX mRNA

NCBI chr10:86,019,216...86,024,326
Ensembl chr10:86,019,588...86,032,350

G

mitochondrial ribosomal protein S18B

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MRPS18B mRNA

NCBI chr20:2,838,174...2,844,260
Ensembl chr20:2,838,030...2,844,260

G

methylsterol monooxygenase 1

increases expression
multiple interactions

prochloraz results in increased expression of MSMO1 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MSMO1 mRNA

NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016

G

neurofibromin 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NF1 mRNA

NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658

G

neuroligin 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NLGN1 mRNA

NCBI chr 2:108,256,236...109,181,530
Ensembl chr 2:108,257,824...109,002,464

G

notch receptor 2

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of NOTCH2 mRNA

NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088

G

notch receptor 3

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of NOTCH3 mRNA

NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025

G

notch receptor 4

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NOTCH4 mRNA

NCBI chr20:4,160,362...4,184,466
Ensembl chr20:4,160,445...4,184,465

G

NPL4 homolog, ubiquitin recognition factor

multiple interactions
increases expression

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of NPLOC4 mRNA
prochloraz results in increased expression of NPLOC4 mRNA

NCBI chr10:105,654,395...105,709,958
Ensembl chr10:105,654,812...105,709,913

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions
increases activity

[NR1I2 protein co-treated with NR1I3 protein co-treated with prochloraz] results in increased expression of CYP1A1 mRNA; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [prochloraz results in increased expression of CYP2B10 protein]; prochloraz binds to and results in increased activity of NR1I2 protein
prochloraz results in increased activity of NR1I2 protein

PMID:16565514 PMID:21115097 PMID:28058446 PMID:33049310

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

[NR1I2 protein co-treated with NR1I3 protein co-treated with prochloraz] results in increased expression of CYP1A1 mRNA; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [prochloraz results in increased expression of CYP2B10 protein]

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

neuronal cell adhesion molecule

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of NRCAM mRNA

NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992

G

neuregulin 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NRG1 mRNA; [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of NRG1 mRNA

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

neurexin 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of NRXN1 mRNA

NCBI chr 6:3,177,788...4,323,848
Ensembl chr 6:3,177,897...4,322,710

G

neurexin 2

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NRXN2 mRNA

NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297

G

neurotrophic receptor tyrosine kinase 2

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NTRK2 mRNA

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

ornithine decarboxylase 1

multiple interactions
decreases expression

prochloraz inhibits the reaction [Testosterone Propionate results in increased expression of ODC1 mRNA]
prochloraz results in decreased expression of ODC1 mRNA

PMID:12377983 PMID:15519604

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

prodynorphin

increases expression

prochloraz results in increased expression of PDYN mRNA

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334

G

progesterone receptor

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PGR mRNA

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

cytochrome p450 oxidoreductase

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of POR mRNA

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

peroxisome proliferator activated receptor alpha

increases expression

prochloraz results in increased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

decreases expression
multiple interactions

prochloraz results in decreased expression of PPARG mRNA
prochloraz binds to and results in increased activity of PPARG protein

PMID:30879083 PMID:33049310

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions
increases expression

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of PPARGC1A mRNA
prochloraz results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

parkin RBR E3 ubiquitin protein ligase

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PRKN mRNA

NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555

G

retinoic acid receptor, alpha

increases activity

prochloraz results in increased activity of RARA protein

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

reelin

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of RELN mRNA

NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211

G

roundabout guidance receptor 1

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ROBO1 mRNA

NCBI chr11:10,580,863...11,621,675
Ensembl chr11:10,580,908...11,620,203

G

retinoid X receptor alpha

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of RXRA mRNA

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

SH3 and multiple ankyrin repeat domains 2

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SHANK2 mRNA

NCBI chr 1:199,146,210...199,590,962
Ensembl chr 1:199,169,429...199,589,394

G

solute carrier family 1 member 2

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SLC1A2 mRNA

NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498

G

solute carrier family 1 member 6

multiple interactions

[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SLC1A6 mRNA

NCBI chr 7:10,841,836...10,870,424
Ensembl chr 7:10,841,837...10,870,449